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Background: Evidence supports a role for iron homeostasis in the pathogenesis of HIV and 
tuberculosis.  The iron regulatory peptide, hepcidin, inhibits both dietary iron absorption and 
iron efflux leading to macrophage iron retention.  Conditions associated with elevated hepcidin, 
which include altered concentrations of ferritin, transferrin and hemoglobin, may favor 
Mycobacterium tuberculosis iron acquisition, HIV progression and anemia.  In light of this, we 
investigated iron homeostasis biomarkers as risk factors for incident TB and mortality in an HIV-
seropositive cohort and also for progression to TB in an HIV-seromixed cohort.  In addition, we 
characterized iron homeostasis during TB therapy in order to identify causes of anemia and 
inform selection of safe, effective and well-timed treatments for anemia. 
Methods: Clinical and demographic data and archived plasma and serum samples from two 
research platforms were utilized in this work: the Medical Research Council (MRC) HIV clinical 
cohort and the MRC TB case contact study.  Analysis of iron homeostasis biomarker 
concentrations was conducted at MRC laboratories in The Gambia.  
Results: During HIV Clinical Cohort follow up, 32 incident tuberculosis cases were identified and 
64% of the 196 participants died.  Greater hepcidin was associated with significantly increased 
likelihood of tuberculosis and greater all-cause mortality.  This was consistent with observed 
higher ferritin and hepcidin concentrations in HIV-seromixed contacts of infectious TB cases 
that progressed to TB earlier.  Analysis of biomarkers and anemia during TB therapy revealed 
that anemia of inflammation was predominant TB diagnosis, declining significantly after six 
 months of treatment; however, a corresponding reduction was not evident for anemia with 
iron-responsive components. Hepcidin concentrations significantly declined after 2 months of 
TB treatment.    
Conclusions: Changes in iron homeostasis biomarkers are associated with incident TB and 
mortality in HIV and progression to TB disease among contacts of infectious TB cases. Further 
studies are needed to elucidate mechanisms and determine the clinical utility of monitoring 
iron homeostasis biomarkers.  TB therapy is associated with significant reductions in anemia of 
inflammation, but iron-based interventions are needed for anemia with iron responsive 
components. Monitoring hepcidin reveals a window for intervention opening as early as two 
months into TB treatment. 
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CHAPTER 1 
Introduction 
Iron 
Iron (chemical symbol: Fe) is one of the most abundant elements in the earth’s crust 
and an essential nutrient for almost all known organisms.  It is able to receive and release 
electrons during conversion from Fe(II) to Fe(III) and plays a major role in DNA production and 
in energy generation (1).  In humans, iron is considered indispensible because it serves as a co-
factor for many proteins, including hemoproteins and enzymes, which are essential for 
fundamental cellular processes (2).  
At a given time, between three and five grams of iron are present in the human body, 
with the majority in the form of heme in hemoglobin.  Macrophages, muscle myoglobin, and 
the liver parenchyma also contain significant portions of body iron.  Absorption of dietary 
inorganic iron occurs through enterocytes via divalent metal transporter 1 (DMT1) following 
reduction of Fe(III) to Fe(II).  Internalization of dietary heme also occurs through enterocytes, 
though the mechanism is not well defined.  Export of iron from enterocytes is mediated by 
ferroportin and coupled with re-oxidation from Fe(II) to Fe(III) by either the ferroxidase 
hephaestin or its homologue, ceruloplasmin. Once exported, iron binds to the iron transport 
protein, transferrin, for delivery to tissues and erythroblasts.  Macrophages acquire iron via 
eyrthrophagocytosis.   
Regulation and assessment of iron status/iron homeostasis 
The potential consequences of “too much” or “too little” iron in the human body are 
dire.  They include oxidative damage, anemia and increased susceptibility to infection.  To avoid 
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these consequences, a system of highly regulated mechanisms is in place to control iron 
homeostasis.  Regulation occurs at both the systemic and cellular levels and influences a 
number of iron-associated proteins including the five proteins that are the focus of this work: 
ferritin, hepcidin, transferrin, soluble transferrin receptor (sTfR) and hemoglobin.  The iron-
related functions of these proteins and their biological mechanisms of effect related to iron 
homeostasis are summarized in Appendix 1. 
There are a plethora of methods available to assess iron status and/or iron homeostasis 
in clinical and research settings.  Measurement of serum/plasma iron, zinc protoporphyrin 
(ZnPP), and transferrin saturation are part of a long list that also includes assessment of 
concentrations of ferritin, hepcidin, transferrin, soluble transferrin receptor (sTfR) and 
hemoglobin.  Of the five proteins that are the focus of this work, the iron storage protein 
ferritin and oxygen transport protein hemoglobin are the most commonly measured.  However, 
sTfR has important clinical utility when inflammation is present, and both transferrin and 
hepcidin are emerging as informative markers. 
Anemia 
When hemoglobin concentration falls below a certain cutoff (which varies by age, sex 
and race (3)), oxygen delivery to tissues is considered to be impaired and the individual with 
low hemoglobin is considered to be anemic.  Anemia affects an estimated one-quarter of the 
world’s population (4), with a disproportionate share of cases occurring in sub-Saharan Africa 
(5).  Consequences of anemia include increased morbidity and mortality (6), decreased quality 
of life (6), and diminished productivity (7).  Causes of anemia are diverse and often act in 
combination with each other.  While the largest worldwide contributor to anemia is thought to 
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be iron-deficiency (4), factors including hemoglobinopathies, other micronutrient deficiencies 
and infection also play important roles in contributing to the worldwide anemia burden.  
While determinants of iron deficiency anemia (IDA) are diverse (e.g., parasitic worms, 
diet, pregnancy) (8), the mechanisms responsible for IDA are straightforward: either decreased 
iron supply impairs hemoglobin production, or bleeding causes the loss of erythrocytes faster 
than they can be replaced.  Other factors that contribute to and cause anemia do so via more 
complex pathways.  Anemia of inflammation (AI) (also referred to in the literature as “anemia 
of chronic disease (ACD)”), is considered to be the second largest contributor to anemia after 
iron deficiency (9).  It is a particularly important factor to consider in settings where anemia co-
exists with high rates of infection.  AI arises as a result of an innate immune response, in which 
pattern-recognition receptors on monocytes, macrophages, neutrophils and dendritic cells 
recognize motifs specific to pathogens and release inflammatory cytokines.  The resulting 
inflammation leads to general alteration of iron homeostasis as well as anemia-causing 
pathologies including short erythrocyte life-span, poor erythrocyte iron incorporation and 
decreased sensitivity to or supply of erythropoietin (10).  
 The iron regulatory protein, hepcidin, plays an important role in the mechanisms 
responsible for AI and the inflammation-mediated alteration of iron homeostasis.  Specifically, 
hepcidin binds to and degrades the iron export protein ferroportin and down-regulates 
expression of the iron importer DMT1.  Since hepcidin transcription is induced by the pro-
inflammatory cytokine, interleukin-6 (IL-6), inflammation leads to a reduction in iron absorption 
and causes iron to be sequestered in macrophages and enterocytes. This mechanism, which is 
supported by numerous in vitro studies (11), contributes to the overall alteration of iron 
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homeostasis that is a hallmark of AI and also limits iron delivery to erythroblasts, functionally 
causing anemia.  Studies conducted in humans support this mechanism and also indicate that 
hepcidin is a predictor of both erythrocyte iron incorporation (12) and the effectiveness of oral 
iron therapy (13).   
Acute Phase Response 
In addition to lower hemoglobin concentrations, the inflammatory cytokines that are 
released upon innate recognition of a pathogen induce changes in plasma concentrations of 
other proteins.  This phenomenon is referred to as the acute phase response (APR) and the 
affected proteins are considered acute phase proteins (APPs). The iron homeostasis proteins 
ferritin, transferrin and hepcidin are considered APPs, as are C-reactive protein (CRP) and alpha-
1-antichymotrypsin (ACT), both of which are often utilized in studies as markers of 
inflammation.  Changes in APPs must be considered when interpreting concentrations of iron 
homeostasis proteins. For example, a study in rural Zambian children reported that 
measurements of serum ferritin were 279-356% higher for those experiencing infection (14).   
Assessing iron homeostasis while also controlling for changes in APPs is a challenge. 
However, innovative indices have been developed that enable researchers and clinicians to 
interpret APPs even when inflammation is present.  For research or clinical work involving iron 
homeostasis proteins the non-APP, soluble transferrin receptor (sTfR), is often utilized.  Soluble 
transferrin receptor (sTfR) is a cleaved portion of transferrin receptor, which is a carrier protein 
necessary for cellular internalization of transferrin.  Since sTfR is regulated primarily by 
intracellular iron concentrations, it can be incorporated into indices in conjunction with iron 
homeostasis proteins that are APPs to assess iron status.  These indices are especially handy in 
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situations where it is important to determine if an apparently iron deficient or sufficient 
individual is actually iron deficient/sufficient or if inflammation is an influencing factor. 
Specifically, the sTfR/log(ferritin) ratio has been widely used as a means by which to distinguish 
AI from IDA and other types anemia (15). 
 
Iron and Infection 
In the context of infection, iron’s limited availability within the human body and its 
physiological importance to both hosts and microbes make it a valuable commodity. Many 
microbes depend on host-acquired iron and, in response; hosts use their complex system of 
iron regulation to modify their iron metabolism and restrict iron availability.   Microbes, in turn, 
employ complex iron acquisition strategies to obtain the restricted resource.   
Since microbes cultured in iron-scarce environments show decreased energy and nucleic 
acid production (16) the prevailing “nutritional immunity” hypothesis (17) suggests that iron-
deficient host environments are better equipped to resist infection than iron-rich host 
environments. While some evidence supports this hypothesis (18-20), the relationship is likely 
more complicated and dependent on the pathogen that is causing the infection.  In general, it 
may be that a proverbial ‘goldilocks zone’ governs the relationship between iron status and 
infection.  Iron deficiency or ‘too little iron’ is known to compromise cell-mediated immune 
function (21) and iron sufficiency or ‘too much iron’ increases iron availability to pathogens 
leading to increased disease susceptibility (18, 22). The optimal or ‘just right’ level of iron status, 
which has not been defined, may maintain immune function while also conferring some 
protection against pathogens.  
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Since this work focuses on iron homeostasis in human immunodeficiency virus (HIV) 
infection, HIV/tuberculosis (TB) co-infection and TB; the following sections will concentrate on 
the prevalence, pathogenesis, diagnosis and treatment of these diseases, as well as the 
research related to iron homeostasis in each context.  
 
Human Immunodeficiency Virus (HIV) Prevalence 
HIV is the world’s leading cause of infectious disease mortality.  It was first identified in 
1980 and it has claimed approximately 36 million lives since. There are currently 35 million 
people living with HIV, the majority of whom reside in sub-Saharan Africa (23).  Worldwide, HIV 
prevalence ranges from approximately 26% of adults aged 15-49 in Swaziland to <0.1% in 
Afghanistan (23).    
Human Immunodeficiency Virus (HIV) Pathogenesis 
HIV is transmitted from human to human via bodily fluids.  Upon entrance into the body, 
the virus identifies and binds to a target cell.  Following binding, HIV’s viral envelope fuses with 
the target cell membrane allowing the HIV capsid and genome to enter the cell.  Once inside, 
HIV utilizes reverse transcription to convert its genetic material from RNA to DNA, which allows 
it to enter the nucleus where it is integrated into the host cell’s DNA.  At this point, HIV is able 
to use host cell machinery to create HIV proteins, which are assembled into new HIV viruses 
and released.  Due to the presence of viral DNA, many cells that are/were targeted by HIV for 
replication sacrifice themselves in an inflammatory process known as pyroptosis (24).  Since HIV 
preferentially targets human CD4+ T cells for replication, many of the cells destroyed are CD4+ 
T cells. This is important because the CD4 receptors on these cells typically work in combination 
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with T cell receptors on antigen presenting cells to coordinate immune system responses to 
antigens.  When CD4+ T cells are destroyed, the ability of the immune system to respond to 
antigens is greatly impaired. 
During initial acute HIV infection, HIV is able to replicate quickly and many CD4+ T cells 
are destroyed.  This phase is short-lived, however, and is typically countered by an immune 
response that leads to an increase in CD4+ T cell numbers and transition into a period of clinical 
latency.  During latency, HIV reproduces at very low levels, which slowly decreases the host’s 
CD4+ T cell count, but does not result in clinical symptoms.  Latency lasts an average of ten 
years without treatment and can last much longer with treatment (25).  When the CD4+ T cell 
count is depleted to less than 200 CD4+ T cells/microliter, the HIV infection is considered to 
have progressed to Acquired Immunodeficiency Syndrome (AIDS).  At this point the ability of 
the immune system to respond to opportunistic infections is severely impaired.  Without 
treatment, people who progress to AIDS are unlikely to survive for more than 3 years (25).  
Drivers of HIV infection are complex and multifactorial.  While CD4+ T cell depletion is 
typically utilized to track HIV progression, interconnected factors including viral replication, 
immune activation, inflammation and microbial translocation are all involved in driving 
progression of the infection.  Anti-Retroviral Therapy (ART), which is a combination therapy that 
targets different stages of the HIV life cycle, is currently the best option for slowing HIV 
progression.  However, strategies such as prophylaxis against opportunistic infections and 
micronutrient supplementation (26) have also been shown to extend lives and reduce the risk 
of immune-decline in HIV-infected people. 
Role for Iron in HIV 
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Iron is required for several steps in the life cycle of HIV, including reverse transcription, 
gene expression and capsid assembly (27).  Emerging evidence from both human and in vitro 
studies suggests that iron is an important regulator of HIV progression and that elevated iron 
status leads to more rapid progression of infection. Specifically, both hereditary iron overload 
(28) and high iron status (29) appear to speed up progression of HIV, while iron chelation slows 
it down (30).  Similarly, in vitro expression of the iron exporter, ferroportin, was associated with 
reduced levels of HIV transcription (31) and increased levels of iron in primary CD4+ T cells have 
been associated with increased HIV replication (20).   
More broadly, in an ART-naïve HIV-seropositive West African cohort a pattern of iron 
redistribution characterized by elevated ferritin, decreased transferrin and decreased 
hemoglobin (32, 33) was associated with mortality in HIV infection.  This finding is consistent 
with a study linking high ferritin to mortality in another HAART-naïve HIV-seropositive cohort 
and also with studies indicating that anemia is a strong morbidity and mortality risk factor in 
HIV infection (34-38). At this point, the mechanisms that link anemia, iron redistribution and 
mortality in HIV infection are not well defined.   
An additional factor that must be considered, but one that increases the complexity of 
the aforementioned mechanisms, is ART.  The studies summarized in Table 3.1 indicate that 
ART reduces the prevalence of anemia in HIV-infected populations, but also suggest that 
anemia remains unresolved in many people even after initiating ART.   
TB Prevalence  
Estimates suggest that approximately one-third of the world’s population is infected 
with TB causing bacteria, also known as the Mycobacterium tuberculosis (Mtb) Complex (MTBC).  
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While the vast majority of infected individuals will never progress from latent TB infection 
(LTBI) to active TB disease, TB is widespread and considered the world’s second leading cause 
of infectious disease mortality. World Health Organization estimates for 2013 indicated that 
there were 9.0 million new cases of TB and 1.5 million deaths from TB worldwide, with the bulk 
of both cases and deaths occurring in Africa and Southeast Asia (39). 
TB Pathogenesis   
While there are several mycobacterial species that make up the MTBC and cause TB, 
most cases of active TB disease are attributed to Mtb.  Transmission of Mtb occurs when an 
individual with active pulmonary TB disease coughs, sneezes, or shouts – liberating tiny 
airborne particles of tubercle bacilli that can be inhaled by anyone in close proximity.  Inhaled 
bacilli make their way to the alveoli of the lungs where they are phagocytosed (internalized) by 
alveolar macrophages.  Phagocytosis is followed by maturation of the phagosome, a process in 
which the chamber containing the Mtb bacilli is subject to acidification, production of reactive 
oxygen/nitrogen species, and release of anti-microbial peptides.  Phagosomal maturation is 
often sufficient to destroy pathogens, but Mtb’s unique cell wall enables it to tolerate and in 
some cases impair the phagosomal maturation process (40, 41).   
Infected macrophages move from the airways into pulmonary tissue where a local 
inflammatory response initiates formation of a granuloma.  The granuloma is a hallmark of TB 
and is characterized by a core of infected macrophages surrounded by monocytes and T 
lymphocytes. In most people infected with Mtb, granuloma formation signals that the host 
immune system has mostly managed to halt the replication and spread of Mtb.  This stage of 
pathogenesis is known clinically as latent TB infection (LTBI).  During LTBI, the host immune 
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system keeps Mtb in check through deployment of phagosomal defense mechanisms and 
promotion of unfavorable conditions within the granumloma, while Mtb enters a state of 
dormancy in which its metabolic activity decreases and its ability to resist host defense 
mechanisms increases (42).  LTBI is asymptomatic and may be short lived or last for the 
individual’s remaining years of life.  
While some individuals progress directly from Mtb infection to active TB disease, most 
experience some form of LTBI between infection and active TB disease (43).  In the 5-10% (43) 
of individuals who progress from LTBI to active TB disease, dormant Mtb reactivates and begins 
replicating within the granuloma.  Due in part to increased metabolic activity by Mtb, the 
granuloma’s previously solid center becomes caseous and begins to lose its structure. 
Eventually the unstructured granuloma ruptures, releasing TB bacilli into the airways (42). The 
mechanisms responsible for reactivation of once-dormant tubercle bacilli are not well 
understood.  Some studies have speculated that resuscitation-promoting factor (Rpf) plays a 
role in inducing reactivation (44).  The Mtb genome contains several Rpf orthologs (44) and a 
2010 study showed that addition of Rpf to sputum from TB patients increased recovery of Mtb 
(45).  Another model suggests that ‘scout’ Mtb organisms may determine whether or not 
broader Mtb reactivation will occur by sensing the attractiveness of the environment for 
replication (42).  In this model limitation of nutrients, including iron, would likely play an 
important role in determining the likelihood of Mtb reactivation.   
TB Diagnosis and Treatment  
Sustained high levels of new TB cases and deaths from TB serve as evidence that 
diagnosis and treatment of TB present major challenges.  TB diagnosis has traditionally been 
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based on a “passive case finding” strategy, in which symptomatic individuals who presented at 
medical facilities were tested for the disease using sputum-smear microscopy and 
mycobacterial culture.  While passive case finding, microscopy and culture are still in wide use, 
recent advances have improved case identification and accelerated TB diagnosis.  In particular, 
community based case finding strategies (e.g., enhanced case finding, in which communities are 
sensitized about TB signs/symptoms and TB contacts are screened) and the Xpert MTB/RIF test 
have had recent impacts (46, 47). These developments are proving to be especially important in 
resource restricted settings where TB prevalence is high and access to labs outfitted for TB 
culture is decreased.   
Upon diagnosis, current treatment guidelines for active TB disease include an intensive 
phase of the anti-TB drugs isoniazid, rifampicin, ethambutol, and pyrazinamide for two months, 
followed by isoniazid and rifampicin for four months (48).  Isoniazid and ethambutol work 
against TB causing bacteria by interfering with mycobacterial cell wall production, rifampicin 
inhibits bacterial RNA synthesis and pyrazinamide impairs mycobacterial fatty acid synthesis.  
With timely diagnosis these drugs are extremely effective.  Cure rates for patients (non-multi-
drug resistant TB) on TB treatment are close to 90% (49).  However, cure rates for untreated TB 
cases or for patients in whom treatment is delayed, are poor.  70% of adults with untreated PTB 
die within 10 years (50) and delayed PTB treatment is linked to increased risk of mortality (51).  
In addition, foregoing or delaying treatment fundamentally increases the likelihood of 
transmission of TB causing bacteria (52).   Similar to patients who experience delays in TB 
treatment, TB patients with co-morbidities who are undergoing treatment are at higher-risk for 
poor TB outcomes. Anemia at TB diagnosis, for example, has been linked to an increased risk of 
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death (53, 54). The same is true for individuals with malnutrition (55), bacterial pneumonia (54), 
and HIV/TB co-infection (56).  Thus, timely diagnosis, swift administration of treatment, and 
resolution of co-morbidities are key components in reducing TB transmission and death from 
TB.   
LTBI Screening and Treatment  
The standard screening method for LTBI is the mantoux tuberculin skin test (TST).  The 
TST is administered as an intradermal injection of a standard volume of tuberculin purified 
protein derivative (PPD) into the inner-forearm.  Results of the test are based on the diameter 
of the induration 48 to 72 hours following administration.  While the TST is generally effective, 
results require several days to obtain and specificity is low in populations vaccinated with the 
TB-vaccine, BCG, due to overlapping antigens present in both the vaccine and PPD (57).  These 
issues likely spurred the recent development of interferon gamma release assays (IGRA), which 
yield results within 24 hours and utilize antigens not found in BCG (58). 
Treatment of individuals at risk for transitioning from LTBI to active TB disease is an 
important strategy in fighting the global TB epidemic.  Treatment for LTBI typically includes 
some combination of self-administered isoniazid and/or rifampetine and is considered to be 
highly effective in decreasing the probability of progressing to active TB disease (59).  The 
challenge in implementing treatment of LTBI is identification of when and in whom treatment 
should be initiated.  The global population with LTBI includes an estimated two billion people, 
and it is unlikely that all of these individuals could or should be subjected to a lengthy course of 
antibiotics. Thus, an important step in treating LTBI will be identifying those individuals who are 
at risk of progressing to TB and in need of treatment. The ability to identify who is at risk for 
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transitioning from an infected and stable state to an infected but disease progressing state is 
critical for both the clinical management of the individual and for the prevention of TB 
transmission at the population level.  Importantly, biomarkers capable of identifying these 
individuals at risk for progression have not yet been established, though early efforts to do so 
using genetics (60), immunological markers (61), and metabolomic profiles (62) are ongoing.   
Role for Iron in TB  
Evidence links iron with TB pathogenesis both from the perspective of the pathogen and 
the host.  Upon infection, host immune recognition of Mtb induces a pro-inflammatory reaction 
that restricts iron access (63).  Since host-acquired iron is a co-factor involved in vital Mtb 
cellular processes, Mtb responds by manufacturing siderophores, molecules capable of binding 
iron more strongly than host iron-storage proteins.  Specifically, Mtb synthesizes two types of 
siderophores: lipophilic, cell-bound mycobactins and free carboxymycobactins, which work 
together to capture iron from a variety of host iron sources (including transferrin, lactoferrin 
and heme (64, 65)) and transfer it across the Mtb cell wall.  This process has been shown to be 
essential for Mtb growth and virulence (66, 67) and capable of increasing iron availability in the 
mycobacterial phagosome almost 20-fold (68).  Evidence highlighting the importance of 
siderophores to Mtb growth is consistent with studies examining the effect of modified iron 
status on Mtb growth.  Decreasing iron availability (regardless of the mechanism) reduces Mtb 
growth, and addition of iron to Mtb almost always enhances growth (63).  Similarly, genetics 
support the important role for iron in Mtb growth.  Mtb mutants with defective genes involved 
in siderophore synthesis (66) and/or iron-utilization machinery (69) show reduced growth.   
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Examination of the role of iron in TB from the perspective of the host echoes its 
importance. Most strikingly, a pattern of altered host iron status characterized by high ferritin, 
low transferrin, and low hemoglobin has been identified as a risk factor for progression to TB 
among HIV-infected individuals (70).  This is consistent with evidence indicating that high 
macrophage iron stores are linked to an increased likelihood of contracting Mycobacterium spp. 
infections (71) as well as studies suggesting that dietary iron overload is associated with an 
increased risk of developing pulmonary tuberculosis (PTB) (72) and dying from TB (73).  It is also 
consistent with studies that have identified anemia is a risk factor for poorer TB outcomes (53, 
54).  From the genetic perspective, polymorphisms in the phagolysosomal iron transporter 
SLC11A1 (NRAMP1) are associated with TB susceptibility (74, 75) and hereditary 
hemochromatosis, which leads to iron deficient macrophages, is thought to be protective 
against TB (76).  
 
HIV/TB Co-Infection Prevalence, Pathogenesis and Treatment  
The probability of developing and dying from TB is significantly higher in people infected 
with HIV.  An estimated 13% of all new TB cases and 27% of deaths from TB in 2013 were in 
HIV-infected people (39). 
Epidemiological evidence suggests that HIV alters the pathogenesis of TB.  Among those 
infected with Mtb, people living with HIV are 12-20 times more likely to progress to active TB 
than those not living with HIV (77).  The mechanisms explaining this altered pathogenesis, 
however, are not clear.  Studies have shown that risk of TB increases with CD4+ T cell depletion, 
but also that a high risk of TB is present when CD4+ T cell counts are higher during the first year 
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following HIV seroconversion (78).  It may be that TB-specific CD4+ T cells are depleted (79) or 
that HIV alters T-cell responses in a way that eases progression from LTBI to active TB. The 
latter is supported by a report that HIV-infected subjects that showed decreased responses to 
Mtb antigens linked with LTBI (80).  Similar studies have also reported that T-cell responses to 
Mtb antigens are influenced by CD4+ T cell counts and ART exposure (81, 82).   
Treatment of HIV/TB co-infection is inclusive of both ART and standard TB treatment.  
ART has been shown to reduce the likelihood of progression to TB (83) and anti-TB treatment is 
recommended upon diagnosis of TB (84).  The World Health Organization (WHO) also 
recommends the use of Isoniazid Preventative Therapy (IPT) for all people living with HIV.  IPT is 
considered safe, and significantly reduces the risk of progression from LTBI to active TB.  The 
WHO considers IPT to be one its three priorities, along with intensified case finding and 
infection control, to reduce the impact of TB on people living with HIV. 
Role for iron in HIV/TB Co-Infection  
A small number of studies have specifically explored the relationship between iron 
homeostasis and TB in the context of HIV, with most focusing on associations at TB diagnosis or 
post TB-diagnosis clinical outcomes.  These studies have linked both iron status to TB 
recurrence (85) and anemia to mortality in HIV/TB co-infection (86).  At the current time, just 
one study has examined iron status prior to TB diagnosis, allowing for an investigation into 
factors associated with TB susceptibility. In this study, which was mentioned previously, a 
pattern of altered host iron homeostasis characterized by high ferritin, low transferrin, and low 
hemoglobin was identified as a risk factor for progression to TB among HIV-infected individuals 
(70).  
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Overall Research Objective 
Given the evidence supporting a role for iron in the pathogenesis of HIV, HIV/TB co-
infection, TB and anemia, the objectives of this research were to characterize changes in iron 
homeostasis and provide insight into the mechanisms governing iron homeostasis in these 
contexts.  Additionally, we aimed to explore the potential clinical utility of monitoring iron 
homeostasis biomarkers at HIV diagnosis, prior to the development of TB disease and during TB 
therapy.   
Specific Aims  
1) To investigate hepcidin concentration as a risk factor for incident TB in HIV infection.  
2) To investigate hepcidin concentration as a risk factor for mortality in HIV and explore 
the broader links between anemia, inflammation and iron homeostasis in HIV.  
3) To investigate iron homeostasis biomarkers as risk factors for progression to active TB 
disease.   
4) To evaluate anemia etiologies and characterize the evolution of iron homeostasis 
biomarkers during TB therapy. 
 
Study Populations and Setting 
The studies described in this document were conducted using archived plasma and 
serum samples from the Medical Research Council (MRC) HIV clinical cohort and the MRC TB 
case-contact platform, both of which were/are based in The Gambia.  Briefly, the HIV clinical 
cohort was started in the late 1980s and included men and women from throughout The 
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Gambia who were recruited at all stages of HIV progression at a time when antiretrovirals 
(ARVs) were unavailable.  The ongoing MRC TB case-contact (TBCC) research platform is 
designed to follow both household contacts of infectious TB cases and TB cases undergoing 
treatment (87).  It includes primarily participants from the urban and semi-urban areas along 
The Gambian coast.  Clinical data and plasma/serum samples were collected from both the HIV 
cohort and the TBCC participants at regular intervals along with demographic data.   
The Gambia is a small country in West Africa geographically surrounded by Senegal 
except for a small stretch of Atlantic Ocean coastline.  The majority of the population of almost 
two million people is concentrated in the urban and semi-urban areas along the coast.  The 
population is primarily Muslim (90%) and includes a variety of ethnic groups (Mandinka, 42%; 
Fula, 18%, Wolof, 16%; Jola 10%; Serahuli 9%; other 4%; non-African, 1%) (88).  The World Bank 
considers The Gambia to be a low-income country, with almost 50% of the population below 
the poverty line (89).   HIV prevalence in The Gambia is estimated to be 1.3%, the 35th highest in 
the world (88). TB incidence in The Gambia is also among the highest in the world, at 173 
cases/100,000 population (39). Other significant health risks in The Gambia include anemia (4), 
malaria, dengue fever, undernutrition, schistosomiasis, meningococcal meningitis and diarrhea.  
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Abstract 
Hepcidin inhibits ferroportin-mediated iron efflux leading to intracellular macrophage iron 
retention possibly favoring Mycobacterium tuberculosis iron acquisition and tuberculosis 
pathogenesis.  Plasma hepcidin was measured at HIV diagnosis in a retrospective HIV-
seroprevalent, antiretroviral-naïve African cohort to investigate the association with incident 
pulmonary and/or extrapulmonary tuberculosis. One hundred ninety-six participants were 
followed between August 5, 1992 to June 1, 2002, with 32 incident tuberculosis cases identified. 
Greater hepcidin was associated with significantly increased likelihood of tuberculosis after a 
median time to tuberculosis of six months.  Elucidation of iron-related causal mechanisms and 
time-sensitive biomarkers that identify individual changes in tuberculosis risk are needed.   
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Introduction
Identifying tuberculosis (TB) risk factors is challenging due to variable disease latencies. 
Host-pathogen iron homeostasis has been previously implicated, and hepcidin, a small liver-
derived peptide that promotes degredation of the intracellular inorganic iron exporter 
ferroportin, may also play a part (1).  Expression is stimulated by pro-inflammatory cytokines 
resulting in ferroportin blockade of iron release from intestinal enterocytes and macrophages.  
Through its influence on host iron homeostasis, hepcidin may promote conditions favorable to 
Mycobacterium tuberculosis (Mtb).  Thus, this study was designed to investigate the 
relationship between hepcidin and susceptibility to TB using a retrospective analysis of a 
longitudinal cohort.    
Methods 
From a historical HIV-seroprevalent cohort in The Gambia (described elsewhere (2)), 196 
participants aged ≥18 years with a plasma sample obtained within three months of HIV 
diagnosis were included. To address temporality, plasma samples were obtained at least 28 
days prior to an incident TB diagnosis and prevalent TB cases excluded. Provisional TB 
diagnoses were independently reexamined according to study-specific incident TB case 
definitions: confirmed pulmonary TB (PTB) was acid-fast bacilli in direct smear/culture from 
sputum/lavage; smear-negative PTB was strongly suggestive clinical symptoms and 
radiographic signs consistent with PTB; and/or confirmed extra-pulmonary TB (EPTB) was acid-
fast bacilli in biopsy/aspirates of a lymph node; probable EPTB was strongly suggestive clinical 
features of EPTB.  Ethical approval was granted by the Joint Gambian Government/MRC, The 
London School of Hygiene & Tropical Medicine and Cornell University.   
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Plasma hepcidin was quantified using a competitive EIA (Bachem, USA). Samples were 
assayed in duplicate and dilutions based on ferritin concentrations.  Hepcidin concentrations 
were interpolated from 4-parameter logistic standard curves. The lower limit of detection (LoD) 
was interpolated at three standard deviations from the all plate mean OD450 readings (wells 
containing diluent in lieu of hepcidin standard or sample).  Undiluted samples <LoD were 
imputed with LoD/2.  Concentrations outside the linear region of the curve or with an intra-
assay coefficient of variation >15% were re-assayed.  As an indicator of inflammation, alpha-1-
antichymotrypsin (ACT) was measured using a nephelometric assay (DakoCytomation Inc, UK). 
Associations were assessed using Poisson regression (STATA/MP 11.1; College Station, 
TX) and expressed as incidence rate ratios (IRR) with incident TB (all TB) as the main outcome. 
Covariates considered a priori were gender and baseline ACT, absolute CD4 cell count, HIV-type, 
age and body mass index (BMI).   
Results 
Incident TB cases (n=32) were identified from 196 participants followed 496 person-
years [median follow-up; interquartile range (IQR)=1.8 years; 1.3 to 2.3].  Median time to TB 
diagnosis was 0.5 years (IQR=0.3 to 1.1).  Baseline differences (median, IQR; mean ± standard 
deviation; frequency) between incident TB and non-cases were not statistically significant for 
hepcidin 22.1, 3.3 to 85.9 ng/ml; CD4 250, 91 to 502 cells/μl; age 34.4±10.3 years; Hb 10.5±2.3 
g/dL; ACT 0.49±0.27 g/L; BMI 19.9±4.3 kg/m2; HIV-1 60.2% and female 55%. 
A dose-response association, with a possible threshold effect, was observed between 
hepcidin and the likelihood of incident TB (Figure 1).  The upper hepcidin quartile was 
associated with the greatest probability of developing TB with the upper quartile accounting for 
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>40% of all incident TB cases.   Comparing the upper hepcidin quartile to the lower three 
quartiles combined revealed a two-fold increase in the incidence of TB [unadjusted incident 
rate ratio (IRR); 95% CI=2.05; 1.01 to 4.16].  The magnitude and direction of associations were 
consistent between the unadjusted and adjusted hepcidin models (Figure 2-top), however, only 
the model with hepcidin adjusted for HIV-type was statistically significant (adjusted-IRR; 95% 
CI=2.10; 1.03 to 4.26).  As expected, a priori considered covariates representing greater 
immunosuppression or inflammation, lower BMI and HIV-1 were associated with non-
statistically significant greater probability of TB in unadjusted models (Figure 2-bottom).   
 
 
Figure 2.1 Incident tuberculosis classified by hepcidin quartiles at HIV diagnosis 
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Figure 2.2  Plasma hepcidin at HIV diagnosis (top) and additional baseline risk factors (bottom) in 
relation to incident tuberculosis 
IRR=Incident rate ratio; BMI=body mass index; ACT=α-1-antichymotrypsin 
Variables were continuous except for: hepcidin concentrations were classified in quartiles with the 
combined lower three quartiles as the referent; absolute CD4 cell counts were classified in clinical 
categories <200, 200-500 and >500 cells/μL as the referent; HIV type was classified as HIV-1 plus HIV-
Dual or HIV-2 as the referent; BMI was classified as <18.5 kg/m2 or ≥18.5 kg/m2 with as the referent.  The 
fully adjusted model included HIV type, absolute CD4 cell count, ACT, age, gender and BMI.  All models 
included 196 participants except for models with missing data for CD4 (182 participants included), BMI 
(151 participants included) and the fully adjusted model (145 participants included). 
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Discussion 
A unique strength of this study is our ability to investigate the temporal association 
between hepcidin as a risk factor for TB susceptibility rather than TB prognosis.  These data 
suggest that in HIV infection, higher hepcidin concentration is associated with a significantly 
greater risk of developing TB.  A recent report from Indonesia indicated median hepcidin 
concentrations at cohort entry were also significantly higher among 45 incident TB cases 
compared to controls with HIV infection (3), however, this was evident only among cases 
diagnosed between 31 to 60 days after cohort enrollment.  Using a different statistical analysis, 
our findings demonstrate that the window may extend further as baseline hepcidin was 
associated with incident TB diagnosed a median of six months after enrollment. While hepcidin 
is most likely part of a complex multi-parameter risk profile with the relevant time period 
remaining to be identified, together these findings suggest rising hepcidin may be a proxy 
biomarker for subclinical TB.   
The mechanisms explaining the association between hepcidin and incident TB in HIV 
infection are unknown.  Hepcidin appears to fit into a larger picture of inflammatory iron 
redistribution including hemoglobin, plasma iron, ferritin, soluble transferrin receptor and 
transferrin that has been previously reported by this group using a larger subset of these same 
cohort participants (4).  Hepcidin has an important regulatory role in host iron homeostasis 
during infection, and pathogen iron homeostasis including both iron acquisition and storage 
influences TB pathogenesis (5-8).  However, how elevated hepcidin modulates the host iron 
environment to favor Mtb is unknown.  Interestingly, emerging evidence suggests that Mtb may 
actually manipulate host cellular hepcidin production (9) to create a pathogen iron-favorable 
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environment.  If this is the case, expanding ongoing research investigating hepcidin antagonists 
(10) to consider hepcidin antagonists in the prevention of TB or augmentation of existing TB 
treatment may be warranted.  
In summary, greater hepcidin concentrations at HIV diagnosis are associated with a 
greater probability of TB with HIV co-infection.   Understanding the relationship between 
hepcidin, host-pathogen iron homeostasis, immune activation/inflammation and TB 
pathogenesis may guide evidence-based decisions in the clinical management of people at high 
risk of iron-deficiency anemia and TB, major health concerns in many regions of the developing 
world.  Overall, this study contributes evidence needed to create a profile identifying who is at 
greatest risk of progressing to clinical TB, and when transition from an infected-stable state to 
an infected-progressing state occurs; obstacles critical to overcome to be able to improve 
individual TB management and population-level TB control.   
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Abstract 
Background: Early and chronic inflammation is a hallmark of HIV infection, and inflammation is 
known to increase hepcidin expression. Consequently, hepcidin may be a key determinant of 
the iron homeostasis and anemia associated with poorer HIV prognoses.    
Objective: To understand how hepcidin is related to anemia, iron homeostasis and 
inflammation at HIV diagnosis, and investigate associations between hepcidin and all-cause 
mortality in HIV infection.  
Methods: In a retrospective cohort, baseline plasma hepcidin was measured by competitive 
enzyme immunoassay within three months of HIV diagnosis in 196 antiretroviral-naïve 
Gambians.  Iron homeostasis (hemoglobin, plasma transferrin, ferritin, iron, soluble transferrin 
receptor) and inflammation (α-1-antichymotrypsin) from the same aliquot were available, as 
were absolute CD4 cell count, age, gender, body mass index and HIV type.   
Results: Anemia was common across the spectrum of immunosuppression (CD4>500 
anemia=68%; 200 to 500=73%; <200=89%, p=0.032), and in men (81%) and women (76%).  
Increasing hepcidin was associated with iron homeostasis biomarkers (higher ferritin and lower 
transferrin, hemoglobin, soluble transfer receptor), inflammation (higher α-1-antichymotrypsin) 
and key health indicators (lower CD4 or body mass index, advancing age, male gender) (p-
values<0.001, except hemoglobin=0.021). Elevated hepcidin was associated with greater all-
cause mortality in a dose-dependent manner (unadjusted Hazard Ratio middle vs. lowest 
tertile=1.95, 95%CI=1.22-3.10; upper vs. lowest: 3.02, 1.91-4.78).  Principal component analysis 
identified two patterns comprised of hepcidin-ferritin-transferrin, with or without α-1-
antichymotrypsin, and iron-soluble transferrin receptor-hemoglobin that may distinguish 
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inflammation and erythropoiesis iron functions.   
Conclusions: Elevated hepcidin is independently associated with greater mortality in HIV 
infection, and hepcidin is also part of a complex relationship linking iron homeostasis, anemia 
and HIV.  Understanding mechanisms and the role of hepcidin modulation may further guide 
evidence-based interventions needed to counter detrimental iron homeostasis and anemia in 
HIV infection.    
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Introduction 
Anemia and abnormal iron distribution are associated with increased morbidity and 
mortality in HIV infection (1-5).  Nutritional causes of anemia including iron, folate and B12 
deficiencies that are considerable in regions affected by poverty (6, 7).  People living in these 
regions are frequently burdened by infectious diseases, and the associated chronic immune 
activation and inflammation they experience fuels anemia of inflammation (AI) (8).   Since iron 
homeostasis is affected by immunological, infectious, clinical and nutritional contributors, it 
acts as a barometer of overall health status.   
Early and chronic immune activation and inflammation is a hallmark of HIV infection.  
Under inflammatory conditions, dietary iron is blocked from enterocyte release, while 
circulating iron is redistributed into cellular storage locations that include macrophages.  This 
affects iron delivery needed for erythropoiesis, and additional HIV-associated consequences 
including myelosuppression, impaired erythropoietin production and opportunistic infections 
further contribute to anemia in HIV infection (9, 10).  These processes may explain why anemia 
is such a common hematological disorder before antiretroviral (ART) therapy is initiated (11).  
While ART reduces the prevalence of anemia for many people, a considerable proportion 
experience unresolved anemia or develop anemia following ART initiation (Table 3.1).    
 Hepcidin is a protein integrally involved in iron homeostasis and anemia through its 
interaction with the only known vertebrate cellular iron exporter, ferroportin (reviewed in (12)).  
Inflammation or excess iron stores lead to up-regulation of hepcidin expression and synthesis, 
while erythropoiesis and hypoxia are negative regulators (13).  Hepcidin inhibits iron efflux from 
duodenal enterocytes and increases intracellular iron retention in iron-recycling macrophages.  
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Recent reports indicate hepcidin may influence multiple HIV outcomes since higher hepcidin 
concentrations were associated with increased in vitro HIV-1 transcription (14), as well as 
greater immunosuppression and tuberculosis among HIV-positive Indonesians (15).  These 
outcomes have been previously linked with other iron-related biomarkers (16-18), suggesting 
that hepcidin is just one contributor to the complex iron biology in HIV infection. Despite the 
importance of hepcidin and the iron regulation associated with anemia, and the link between 
hepcidin and inflammation that has been demonstrated in other clinical conditions (19-21), the 
role of hepcidin in the context of HIV infection and HIV-related anemia remains undetermined.  
Consequently, this study was designed to characterize hepcidin concentrations at HIV diagnosis 
in relation to anemia, iron homeostasis and inflammation, and to investigate hepcidin as an 
independent risk factor for mortality in HIV infection in a region where both infectious and 
nutritional contributors are common.  
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Table 3.1. Anemia in HIV infection in Africa  
Study Participant 
characteristics 
Definition of anemia  Anemia at 
ART 
initiationa 
Pre-ART anemia 
risk factors 
Persistent or 
incident anemia 
after ART initationb 
Post-ART 
anemia risk 
factors  
Johannessen A, Naman 
E, Gundersen SG, Bruun 
JN. BMC Infect Dis 
2011,11:190. 
 
Adults in rural 
Northern 
Tanzania  
Mild anemia:  
Hb<13 g/dL for males  
Hb<12 g/dL for 
females 
Moderate anemia: 8-
10 g/dL 
Severe anemia: <8 
g/dL  
Total: 77.4% 
(649/838) 
Mild: 32.1% 
Moderate: 
(28.4%) 
Severe: 
(16.9%) 
41.9% of 
anemia was 
microcytic  
Female 
Advanced WHO 
Stage 
Low BMI 
Tuberculosis 
Microcytosis  
Hypochromia 
Total: 38.2% 
(39/102) 
After 12 months on 
ART 
Mild: (29.4%) 
Moderate: (6.9%) 
Severe: (2%) 
Low MCV at 
ART initiation, 
Zidovudine-
containing 
initial regimen 
Moh R, Danel C, Sorho S, 
et al. Antivir Ther 
2005,10:615-624. 
Adults in 
urban Cote 
d’Ivoire 
Hb<10.5 g/dL 31%  28% after 3 Months 
on HAART; 
17% after 6 months 
on HAART 
Low baseline 
Hb 
Forna F, Moore D, 
Mermin J, et al. J Int 
Assoc Physicians AIDS 
Care 2009,8:128-138. 
Adults in rural 
Uganda  
Hb≤10 g/dL   25.6% (279/1089) 
After (media=34.2; 
IQR=10.1-36.8) 
months (median) on 
ART 
Anemia at 
baseline 
>12 months of 
d4T before 
switch 
zidovudine 
Kiragga AN, Castelnuovo 
B, Nakanjako D, Manabe 
YC. J Int AIDS Soc 
2010,13:42. 
Adults in 
Uganda 
Hb≤9.5 g/dL 
Hb≤8 g/dL for severe 
anemia 
15% 
(821/5494) 
5.4% 
(296/5494) 
for severe 
anemia 
For severe 
anemia:  
Female  
Advanced HIV 
stage 
4% after  
6 months of ART for 
severe anemia 
Baseline severe 
anemia 
Incident 
tuberculosis 
Low MCV 
Rawat R, McCoy SI, 
Kadiyala S. J Acquir 
Adults in 
Uganda 
Hb<10 g/dL 7.7% 
(55/716) 
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Immune Defic Syndr 
2013,62:246-253. 
Mugisha JO, Shafer LA, 
Van der Paal L, et al. 
Trop Med Int Health 
2008,13:788-794 
Adults in rural 
Uganda 
Hb<12 g/dL for males  
Hb<11 g/dL for 
females 
18.9% 
(49/259)  
Female  
Advanced WHO 
stage 
Low CD4 
Wasting 
  
Jaganath D, Walker AS, 
Ssali F, et al. AIDS Res 
Hum Retroviruses 2014. 
 
Children, 
reproductive 
age adults and 
older adults in 
Uganda and 
Zimbabwe 
Adults:  
Hb<12 g/dL for males  
Hb<11 g/dL for 
females 
Children:  
Hb<10.5 g/dL (ages 5-
11) 
Hb<11 g/dL (ages 12-
14) 
43% 
(1527/3580) 
30% of 
anemia was 
microcytic  
 13% after approx. 10 
months  
(96 weeks) on ART 
12% of anemia was 
microcytic  
Older adults 
Female 
Low BMI  
Microcytosis  
Takuva S, Maskew M, 
Brennan AT, et al. J Trop 
Med 2013,2013:162950. 
Adults in 
Johannesburg, 
SA 
Hb<10 g/dL 25.8% Female 
Younger  
Advanced WHO 
stage 
Tuberculosis 
Incident 
anemia=16.7/1000 
person-years 
between 3 and 6 
months after starting 
ART 
Female gender  
Low BMI 
Advanced WHO 
Stage 
Low CD4 
AZT use 
Owiredu WK, Quaye L, 
Amidu N, Addai-Mensah 
O. Afr Health Sci 
2011,11:2-15. 
Adults in the 
Upper-East 
region (rural) 
of Ghana 
Hb≤10.5 g/dL  63%  46% after 3+ months 
on HAART 
 
Ferede G, Wondimeneh 
Y. BMC Hematol 
2013,13:8. 
Ethiopia 
Adults  
Hb<13 g/dL for males  
Hb<12 g/dL for 
females 
35% 
(138/400)  
Female gender 
Low CD4  
  
Adane A, Desta K, 
Bezabih A, et al.. Ethiop 
Med J 2012,50:13-21. 
Adults in 
urban Ethiopia 
 52.6%  Female gender 37.4% after 4 
months on ART 
Female gender 
Gedefaw L, Yemane T, 
Sahlemariam Z, Yilma D.  
Children, 
adults and 
Adults:  
Hb<13 g/dL for males  
29.9%  Opportunistic 
infections 
16.2% after 3+ 
months on HAART 
HAART regimen 
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PLoS One 2013,8:e72202 older adults in 
Southwest 
Ethiopia 
Hb<12 g/dL for 
females 
Children:  
Hb<12 g/dL (ages 12 
to <15y) 
Hb<11.5 g/dL 
(ages 5 to <12y) 
Hb<11 g/dL (ages 0.5 
to <5y)  
Low CD4 
Rural residence 
Duration of 
HAART 
Tadesse K, Haile F, Hiruy 
N. PLoS One 
2014,9:e87392. 
Adults in 
Northern 
Ethiopia 
<11 g/dL 43% 
(223/520) 
   
Munyazesa E, Emile I, 
Mutimura E, et al. BMJ 
open 2012,2. 
Adult women 
in Rwanda 
<12 g/dL 24.7% 
(165/669) 
Low BMI 
Low CD4 
  
ART=antiretroviral therapy; BMI=body mass index; HAART=highly active antiretroviral therapy; Hb=hemoglobin; MCV= mean 
corpuscular volume with microcytic anemia=MCV defined as <80 fL; WHO=World Health Organization  
a Inclusive of mild, moderate and severe anemia for ART-naïve individuals initiating ART or HAART and not initiating ART or 
HAART(due to lack of availability and/or standard of care when the studies were conducted) 
b Inclusive of both incident and persistent anemia in individuals taking ART or HAART for at least 3 months, specific definitions of ART 
and HAART can be found in the references articles 
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Methods 
Study setting 
Participants were recruited from a larger prospective cohort study (22) and sub-study 
(16, 23) of HIV-positive Gambians. Eligibility criteria included ≥18 years and an existing baseline 
plasma aliquot archived within three months of first HIV diagnosis.  Cohort participants were 
provided free clinical care at the Medical Research Council Unit in The Gambia in accordance 
with national HIV guidelines in effect at the time of participation, including cotrimoxazole 
prophylaxis and symptom management.  Viral load analysis was unavailable for routine 
monitoring at the time of sample collection.  Ethical approval for this study was granted by the 
Joint Gambian Government / Medical Research Council Ethical Review Committee, The London 
School of Hygiene & Tropical Medicine and Cornell University.   
Follow-up and all-cause mortality ascertainment  
Participants (n=196) enrolled between August 5th, 1992 and August 22, 2001, with 
follow-up observation continuing until June 1, 2002.  All-cause mortality was ascertained at 
study clinic visits scheduled every three months. Participants who missed appointments were 
considered lost-to-follow-up if their mortality status could not be determined by medical 
records or at home visits.  Participants were censored on the last date they were known with 
certainty to be alive defined as the last date of clinic attendance or the last date seen by a 
fieldworker or the end of the study observation period.  As common in this region of Africa, 
cause-specific mortality was unavailable since autopsies, including verbal autopsies (24), were 
not routine. 
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Hepcidin, anemia, iron homeostasis and inflammation  
All iron assays were performed using a single heparinized plasma aliquot that was 
stored at -80⁰C.  This single plasma sample was thawed, and then subdivided into multiple 
microvials and refrozen at -80⁰C.  A single microvial was obtained from the freezer and thawed 
for a second time until batch processing of each analyte.  The period between refreezing and 
hepcidin analysis was longer than for other analytes.  While the long-term stability of hepcidin 
is unknown due the relatively recent commercial availability of this assay, the presence of four 
disulfide bonds in the folded structure suggests that the peptide should maintain long-term 
stability (25).  Assay quality controls provided by the assay manufacturer were used and 
performed within manufacturer-defined limits and pooled plasma obtained from a local blood 
bank was used to assess quality assurance.  Hepcidin concentrations were measured in 
duplicate using a competitive enzyme immunoassay (Bachem, Peninsula Laboratories, San 
Carlos, CA) according to the manufacturer’s protocol (26, 27).  Samples were diluted based on 
known ferritin concentrations in supplied standard diluent (peptide-cleared human serum) and 
analyzed using a 9-point 2-fold serial dilution (maximum concentration, 25 ng/mL) standard 
curve. Hepcidin concentrations were interpolated from 4-parameter logistic standard curves 
generated by readerfit (www.readerfit.com).  The lower limit of detection of 0.40 ng/ml was 
interpolated at three standard deviations from the all plate mean (e.g. wells containing diluent 
in lieu of hepcidin standard or sample). The 11 undiluted samples with limits of detection <0.40 
ng/ml were imputed with a value of limit of detection/2.  Samples with concentrations outside 
the linear region of the curve, or those with an intra-assay coefficient of variation >15%, were 
reanalyzed using appropriate dilutions.   
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Soluble transferrin receptor (sTfR) (R&D Systems, Abingdon, UK) and ferritin (Immuno-
biological Laboratories, Hamburg, Germany) were measured by ELISA, and limit of detections 
were <3 and >80 nmol/L, and <2.5 and >1000 µg/L, respectively; samples with values outside of 
these ranges were imputed with the limit of detection value.  Plasma iron was assessed using 
an endpoint assay (ABX Diagnostics, Shefford, UK) and transferrin by turbidimetry (ABX 
Diagnostics, Shefford, UK).  Hb concentrations were measured with a hematology analyzer 
using routine procedures in the clinical laboratory (Coulter MD II, Coulter Corporation, USA), 
and values obtained from study databases.  Alpha-1-antichymotrypsin (ACT), as an indicator of 
inflammation, was measured using a nephelometric assay (DakoCytomation Inc, Ely, UK). 
Statistics  
STATA/MP 11.1 (College Station, TX) was used for statistical analyses.  Data 
transformation included categorization of Hb, ferritin, sTfR and iron according to clinical 
reference ranges. Inspection of raw data suggested using only the clinical reference range 
would obscure meaningful transferrin associations, and transferrin was reported according to 
both clinical reference limits and tertiles.  In the absence of an established clinical reference 
range for hepcidin, hepcidin was classified into tertiles.  ACT is primarily a research analyte and 
a clinical reference range was not provided by the manufacturer  or recommended by others 
(28), however, for this statistical analysis, a frequently cited cut-off range was used (29).   
Scatterplots and boxplots were used to graphically present bivariate associations 
between hepcidin and Hb, iron homeostasis and inflammation biomarkers, as well as the a 
priori considered potential covariates [body mass index (BMI), age, absolute CD4 cell count, 
gender, HIV type].  Pearson correlation coefficients, Wilcoxon rank sum, ANOVA, Student’s t-
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test, Spearman or χ2 were used to test these associations, with a p-value <0.05 considered 
statistically significant . A Kaplan–Meier survival curve was used to graphically represent the 
probability of survival from HIV diagnosis according to hepcidin tertiles and compared using the 
Log-rank test.  Univariable and multivariable Cox regression models with all-cause mortality as 
the main outcome were analyzed.   
Principal Component Analysis (PCA) was chosen as a variable reduction technique given 
the potential redundancy (e.g. correlation) in the measured iron homeostasis (transferrin, 
ferritin, iron, Hb, sTfR) and inflammatory (ACT) variables. Essentially, the goal of PCA was to 
reduce the number of observed variables to allow concentration on only those that principally 
contribute to variation in a meaningful way.  This was done by statistically identifying groups of 
variables that “travel together” in components (e.g. patterns), while at the same time, 
disregarding those variables that only contribute in a negligible way.  Identified patterns 
represent distinct groups that are uncorrelated from other patterns. Decisions regarding which 
components were meaningful to retain was based on the a priori criterion of eigenvalue-one 
(patterns with eigenvalues >1 were considered to contribute principally).   
 PCA was conducted with iron and inflammatory variables categorized in tertiles and also 
as continuous variables; since similar results were obtained, only tertile models reported.  After 
identifying principal patterns of iron and inflammation groupings, principal component (PC)-
scores were calculated for each individual.  These scores represent a linear algebraic equation 
accounting for the weighting of each observed variable.  PC-scores were modelled as a 
continuous variable and analyzed in unadjusted and adjusted Cox regression.  An iron 
homeostasis index was also calculated for each participant based on the PCA-identified pattern 
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groupings.  The iron homeostasis index conceptually represents the magnitude of iron deviation 
and combined impact on mortality. It was calculated using the observed concentrations 
measured for each iron and inflammatory variables classified into tertiles.  A value of 1 was 
assigned to the lowest hazard ratio associated with each biomarker. In these data, the lowest 
hazard ratios were associated with the lowest tertile of hepcidin, ferritin, sTfR, ACT and the 
highest tertiles of transferrin, iron and hemoglobin.  All intermediate tertiles were assigned a 
value of 2; and all remaining tertiles were assigned a value of 3 (e.g. those associated with the 
greatest hazard ratios).  Values were summed for each individual providing an overall iron 
homeostasis index specific for each individual and each PCA-identified pattern. The iron 
homeostasis index was modelled as a single continuous variable and analyzed using unadjusted 
and adjusted Cox regression.  
Results  
Subjects 
Characteristics of the 196 cohort participants are summarized in Table 3.2.  During the 
10-year cohort follow-up period, 64% of participants died (n=125), 19% (n=37) were censored 
at the last date with known certainty to be alive and 17% (n=34) were alive at study closure.  
Participants censored prior to death or study closure were more likely to have greater absolute 
CD4 cell counts like commonly observed in resource-restricted regions without universal ART 
access, and in this study, were also more likely to be younger and female.   
Hepcidin and association with iron homeostasis, anemia and inflammation in HIV  
Hepcidin was positively correlated with ferritin and ACT and inversely correlated with 
Hb, transferrin and sTfR, but not plasma iron (Figure 3.1).  Higher hepcidin concentrations were 
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correlated with lower absolute CD4 cell counts or BMI and advancing age, but there was no 
apparent association with HIV type (Figure 3.2).  While males had higher hepcidin than women 
(median, IQR hepcidin: men=52.4, 16.7 to 96.9 vs. women=11.9, 2.4 to 58.6 ng/m; p<0.001), 
males were also experiencing greater immunosuppression at HIV diagnosis (median, IQR CD4 
cells/μl: men=191,136 to 255 vs. women=292, 218 to 399; p<0.001).   
Table 3.2 summarizes participant characteristics according to anemia classification.  
Anemia was associated with a lower mean BMI and more advanced immunosuppression as 
expected, but anemia was also common across the spectrum of immunosuppression (CD4>500 
anemia=68%; 200 to 500=73%; <200=89%, p=0.032), and in both men and women (frequency 
of anemia in men=81%, women=76%; mean ± SD Hb concentration in men=10.3 ± 2.6, 
women=10.7 ± 2.1 g/L).  Anemia was associated with a greater degree of inflammation as 
indicated by greater ACT concentrations (anemia vs no-anemia: 0.43 vs 0.32 g/L; p=0.003), as 
well as an inflammation-induced iron redistribution profile typified by comparatively greater 
hepcidin and ferritin and lower transferrin and iron concentrations (p-values <0.09). While sTfR 
concentrations were higher in the anemic group suggesting the presence of iron deficiency or 
co-existing iron deficiency plus AI, the sTfR/log10 ferritin ratio was not significantly different 
between those with or without anemia.   
Hepcidin and mortality in HIV 
Figure 3.3 demonstrates a dose-response relationship between greater hepcidin at HIV 
diagnosis and increasing probability of all-cause mortality.  This relationship is further 
supported in unadjusted Cox regression analysis, however, the adjusted association was 
attenuated and not statistically significant (Table 3.3).  Like hepcidin, all other iron homeostasis 
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and inflammatory associations were attenuated in regression models adjusting for HIV type, 
age, gender, BMI, immunosuppression at HIV diagnosis, with or without additional adjustment 
for ACT.  Anemia, very elevated ferritin and the lowest transferrin tertile remained statistically 
significant in adjusted analyses.   
Principal component analysis of iron homeostasis and inflammation in HIV 
Using PCA (Table 3.4), two unique patterns were identified that accounted for 
considerable cumulative variance (68%) in a PCA model with all iron homeostasis variables 
(PCA1).  The first pattern (PCA1.1) was greatly influenced by the trio of hepcidin-ferritin-
transferrin that together explained 43% of the total variance.  The second pattern (PCA1.2) was 
primarily influenced by plasma iron-sTfR-Hb, explaining 25% of the variance.  Notably, the 
identified patterns were driven by non-overlapping principal components (e.g. the observed 
variables did not contribute in a meaningful way to both patterns).  In a second model (PCA2) 
that included all iron homeostasis variables plus ACT, similar grouping patterns were identified.  
In this model that accounted for 66% of the variance, the first pattern (PCA2.1) explaining 45% 
of the variance was dominated by the quartet of hepcidin-ferritin-transferrin-ACT, and the 
second pattern (PCA2.2) explaining 21% of the variance was again primarily influenced by 
plasma iron-sTfR-Hb.  In both PCA models, the principal component eigenvectors (e.g. the 
relative weighting attributed to each of the variables within a specified pattern) between 
hepcidin, ferritin, transferrin with or without ACT were of comparative magnitude, while iron 
was comparatively more influential than sTfR or Hb.   
Mortality associations using predicted PC-scores, as well as an iron homeostasis index 
based on PCA-identified patterns, are presented in Table 3.4.  PC-scores derived from 
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weightings assigned to variables in patterns PCA1.1 (hepcidin-ferritin-transferrin) or PCA2.2 
(hepcidin-ferritin-transferrin-ACT) were significantly associated with mortality in unadjusted 
and adjusted analysis, whereas the PC-scores derived from variables that grouped together in 
patterns PCA1.2 or 2.2 (both included iron-sTfR-Hb) were not. Analysis of the iron homeostasis 
index demonstrated that as the degree of iron deviation typified by the combination of 
elevated hepcidin, elevated ferritin and lower transferrin (PCA1.1) or elevated hepcidin, 
elevated ferritin, lower transferrin and elevated ACT (PCA2.1) increased, so did the mortality 
hazard ratio in unadjusted and adjusted models, although adjusted associations were 
attenuated.  Like the PC-scores modeling, the iron homeostasis index reflecting lower iron, 
higher sTfR and lower Hb was associated with increased likelihood of mortality.  In both the PC-
score and iron homeostasis index models, the associations with hepcidin, ferritin, transferrin, 
with or without ACT, were comparatively stronger than for iron, sTfR and Hb.   
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Table 3.2. Characteristics of cohort participants at HIV diagnosis 
 Overalla 
n=196 
Anemiab 
n=110 
No Anemia 
n=30 
P-valuec 
Cohort person-years 1.8 (0.6 to 4.1) 1.2 (0.5 to 3.3) 4.1 (1.7 to 7.9) <0.001 
Age (years) 34.3 ± 9.8 33.0 ± 8.8 34.6 ± 10.1  0.42 
Female 55%  53%  60% 0.48 
HIV status    0.65 
HIV-1 60% 65% 60%  
HIV-2 39% 35% 40%  
HIV-duald 1% 0% 0%  
Absolute CD4 (cells/μl) (n=182) 250 (92 to 503) 233 (77 to 498) 408 (243 to 699) 0.003 
Body mass index (kg/m2) (n=178) 19.7 ± 4.0 19.2 ± 3.5 21.6 ± 5.1 0.005 
Body mass index <18.5 kg/m2, % 37% 33% 33%  
α-1-antichymotrypsin (g/L) 0.41 (0.31 to 0.58) 0.43 (0.39 to 0.46) 0.32 (0.28 to 0.36) 0.003 
Hepcidin (ng/mL)  22.1 (3.3 to 85.9) 32.2 (2.2 to 88.7) 6.8 (2.1 to 53.3) 0.06 
Ferritin (μg/L)  161 (37 to 534) 158 (36 to 643) 90 (28 to191) 0.09 
Transferrin (g/L)  1.80 ± 0.64 1.75 ± 0.67 2.00 ± 0.50 0.06 
Iron (μmol/L)  9.0 (6.4 to 14.4) 8.5 (6.4 to 12.6) 15.0 (10.0 to 18.8) <0.001 
Soluble transferrin receptor (nmol/L)  24.4 (17.0 to 35.5) 25.3 (21.5 to 28.2 ) 19.8 (16.6 to 23.0) 0.020 
Soluble transferrin receptor/log10 ferritin 11.1 (7.1 to 19.0) 11.3 (7.3 to 18.7) 10.4 (6.5 to 24.1) 0.55 
Hemoglobin (g/L) (n=140) 10.5 ± 2.3 9.6 ± 1.7 13.8 ± 1.1 <0.001 
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IQR, interquartile range; n, sample size; SD, standard deviation. 
aFor normally distributed continuous variables, data presented as mean ± standard deviation; non-normally distributed continuous 
variables presented as median and interquartile range; categorical variables presented as frequency.  
bAnemia was defined according to WHO definition of Hb male <13; female <12 g/d (30).  Hb was available for 140 participants, 
therefore the anemia and no anemia participants totals 140.   
cP-values calculating by comparing group means (Student’s t-test for normal distribution, continuous and Wilcoxon rank-sum test for 
non-normal, continuous) and or frequencies (χ2 test) between anemic vs. non-anemic groups. 
dGiven the small number of HIV-dual diagnoses, HIV-2 was combined with the HIV-1 group for subsequent analyses. 
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Figure 3.1. Scatterplot and correlation coefficients (r) with corresponding p-values between 
circulating hepcidin concentration at HIV diagnosis (ng/ml, log10 scale, y-axis) of HIV Clinical 
Cohort participants, The Gambia (1992 to 2001) and: (A) plasma ferritin (μg/L, log10 scale), (B) 
hemoglobin (g/L), (C) plasma transferrin (g/L), (D) plasma soluble transferrin receptor (nmol/L, 
log10 scale), (E) plasma iron (μmol/L, log10 scale) (F) age (years), (G) α-1-antichymotrypsin (g/L, 
log10 scale), (H) body mass index (kg/m2).  
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A. r=0.76; p < 0.001                                              B. r=-0.20; p < 0.021 
 
 
C. r=-0.61; p < 0.001 
 
D. r=-0.38; p < 0.001 
 
 
E. r=-0.01; p=0.88                                                          F. r=0.27; p <0.001 
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G. r=0.57; p <0.001 
 
H. r=-0.26; p=0.001
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A. 
  
B. 
 
C. 
 
Figure 3.2. Box-plots of circulating hepcidin concentrations (ng/mL; log10 scale) at HIV diagnosis 
of HIV Clinical Cohort participants, The Gambia (1992 to 2001) categorized according to: (A) 
absolute CD4 cell count (cells/μl): <200 (median: 62.8; IQR=18.5 to 175.9), 200-500 (median: 
46.5; IQR=3.9 to 87.3), >500 (median: 20.2; IQR=1.7 to 44.8) (p<0.001); (B) gender: male 
(median: 52.4; IQR=16.7 to 96.9), female (median: 11.9; IQR=2.4 to 58.6) (p<0.001); and (C) HIV 
type: HIV-1 plus HIV-Dual (median: 41.8; IQR=6.2 to 93.7), HIV-2 (median: 19.4; IQR=3.1 to 75.3).  
HIV-Dual was grouped with HIV-1 due to small numbers (n=2) (p=0.40). Differences in mean 
log10-transformed hepcidin concentrations were evaluated using Student’s t-test or ANOVA. 
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Figure 3.3. Kaplan-Meier survival curves according to hepcidin tertiles at HIV diagnosis 
Lowest hepcidin tertile ≤7.8 ng/mL; intermediate >7.8 to <57.6; highest ≥57.6 ng/ml
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Table 3.3.  Cox regression modelsa of hepcidin, iron homeostasis and inflammation and associations with all-cause mortality in HIV 
infection 
Biomarker Concentration at HIV 
diagnosis 
Clinical cutoff or 
tertile limitsb 
Univariate models, 
HR (95% CI)c 
Adjusted models, HR 
(95% CI)c, d 
Adjusted models plus  
α-1-antichymotrypsin, HR 
(95% CI)c, e 
Hepcidin (ng/ml) Lowest tertile ≤7.8 Reference  Reference  Reference  
Intermediate  >7.8 to <57.6 1.95 (1.22 to 3.10) 0.96 (0.56 to 1.63) 0.97 (0.56 to 1.67) 
Highest  ≥57.6 3.02 (1.91 to 4.78) 1.07 (0.61 to 1.87) 1.11 (0.59 to 2.08) 
Ferritin (μg/L) Lower than normal <12  0.62 (0.31 to 1.21)  0.61 (0.29 to 1.25) 0.58 (0.28 to 1.21) 
Normal Seef Reference  Reference  Reference  
Elevated Seef 2.10 (1.37 to 3.23) 1.57 (0.97 to 2.51) 1.90 (1.14 to 3.18) 
Very elevated >1000 3.91 (2.44 to 6.28) 2.09 (1.19 to 3.67) 2.78 (1.49 to 5.17) 
Transferrin (g/L) Highest tertile ≥1.89 Reference  Reference  Reference  
Intermediate >1.47 to <1.89 2.42 (1.37 to 4.24) 0.78 (0.39 to 1.57) 0.79 (0.40 to 1.58) 
Lowest ≤1.47 4.36 (2.85 to 6.66) 1.92 (1.12 to 3.31) 2.13 (1.21 to 3.75) 
Transferrin (g/L) Lower than normal <2.0 2.81 (1.81 to 4.37)  1.02 (0.57 to 1.84) 1.03 (0.57 to 1.88) 
Normalg 2.0 to 3.6 Reference Reference  Reference  
Iron (μmol/L) Lower than normal <20 1.24 (0.87 to 1.77) 1.02 (0.68 to 1.53) 1.02 (0.68 to 1.54) 
Normalh 20 to 55 Reference  Reference (n=168) Reference (n=168) 
Elevated >55 0.93 (0.22 to 3.82) 0.91 (0.60 to 1.37) 0.78 (0.18 to 3.27) 
Soluble transferrin 
receptor (nmol/L) 
Lower than normal <10.6 0.87 (0.35 to 2.16) 0.52 (0.2 to 1.35) 0.52 (0.20 to 1.35) 
Normali 10.6 to 29.9h Reference  Reference  Reference  
Elevated >29.9 1.05 (0.73 to 1.53) 0.91 (0.60 to 1.38) 0.90 (0.58 to 1.38) 
Hemoglobin (g/L) Anemic  See footnotej 3.26 (1.75 to 6.07) 2.75 (1.31 to 5.76) 2.72 (1.29 to 5.72) 
Non-anemic See footnotej Reference  Reference  Reference  
α-1-antichymotrypsin 
(g/L) 
Lower than normal <0.2 0.74 (0.10 to 5.33) 0.95 (0.12 to 7.38) NA 
Normalk 0.2 to 0.6 Reference  Reference  NA 
Elevated >0.6 1.89 (1.27 to 2.80) 1.00 (0.60 to 1.66) NA 
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CI, confidence interval; HR, Cox regression hazard ratio; NA, not applicable. 
aUnadjusted models sample size=196, except for 140 for hemoglobin models; adjusted models have168, except for 119 for 
hemoglobin models due to missing data. 
bThere is no established clinical reference range for hepcidin, and distribution of raw transferrin data indicated tertile classification 
was informative and therefore both tertiles and clinical-cutoffs included for transferrin.    
cThe category with the lowest risk of mortality served as the reference category.  
dAdjusted for HIV type (HIV-1 plus HIV-dual or HIV-2), age, gender, body mass index, and absolute CD4 cell  count (>500, 200 to 500, < 
200 cells/µL) at HIV diagnosis. Gender was not included in regression models where gender used to establish clinical cut-offs (anemia, 
ferritin); and age not included when age used to classify ferritin categories. 
eAdjusted for ACT (continuous) plus all variables in footnotec.  
fFerritin normal reference ranges: 18 to 44 years: men 12 to 200 μg/L, women 12 to 150 μg/L; ≥45 years: men 12 to 300 μg/L, women 
12 to 200 μg/L (31).   
gTransferrin normal reference range: 2.0 to 3.6 g/L (32); no participants had above normal transferrin concentrations.  
hIron normal reference range: 20 to 55 μmol/L (32) 
iSoluble transferrin receptor normal reference range: (33) 
jAnemia: Hb <13 g/L for men; Hb <12 g/L for women (30). 
kACT normal reference range: 0.2 to 0.6 g/L (32).  A normal reference range was not provided by the assay manufacturer, and given 
assay method sensitivity and inconsistencies regarding the existence of a “normal” reference range for ACT, the normal limits should 
be interpreted with these considerations (28).  
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Table 3.4. Principal components analyses of iron homeostasis and inflammatory variables and Cox regression analyses of all-cause 
mortalitya 
PCA model Grouping 
pattern 
identified by 
PCA 
Total 
variance 
explained 
by pattern 
Principal 
Components 
contributing 
to grouping 
pattern 
Principal 
Component 
Eigen-vectorb 
Principal 
Component-
Scoreb, 
unadjusted 
Hazard Ratios 
(95% CI) 
Principal 
Component-
Scorec, 
adjustedd 
Hazard Ratios  
(95% CI)  
Iron 
Dysregulation 
Indexe, 
unadjusted 
Hazard Ratios  
(95% CI) 
Iron 
Dysregulation 
Indexe, 
adjustedd 
Hazard Ratios  
(95% CI) 
PCA1g 
 
Pattern 1 
(PCA1.1) 
43.4% Hepcidin 0.54 1.72 
(1.49 to 1.99) 
1.31 
(1.07 to 1.61) 
1.37 
(1.26 to 1.50) 
1.13 
(1.00 to 1.27) Ferritin 0.54 
Transferrin 0.53 
 
Pattern 2 
(PCA1.2) 
24.7% Iron 0.63 1.08 
(0.93 to 1.27) 
1.00 
(0.83 to 1.20) 
1.15 
(1.03 to 1.29) 
1.08 
(0.80 to 1.45) sTfR 0.54 
Hemoglobin 0.49 
PCA2h 
 
Pattern 1 
(PCA2.1) 
44.8% Hepcidin 0.48 1.64 
(1.44 to 1.87) 
1.26 
(1.05 to 1.51) 
1.28 
(1.19 to 1.37) 
1.08 
(0.99 to 1.89) Ferritin 0.48 
Transferrin 0.46 
ACT 0.45 
 
Pattern 2 
(PCA2.2) 
21.3% Iron 0.61 1.06 
(0.90 to 1.24) 
0.98 
(0.82 to 1.18) 
1.15f 
(1.03 to 1.29) 
1.08f 
(0.80 to 1.45) sTfR 0.56 
Hemoglobin 0.46 
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ACT, α-1-antichymotrypsin; CI, confidence interval; PCA, principal component analysis; sTfR, soluble transferrin receptor. 
aUnadjusted models sample size=196, except for 140 for hemoglobin models; adjusted models have 168, except for 119 for 
hemoglobin models due to missing data. 
bOrdered by relative loading or impact of eigenvector (e.g. weighting of individual variable, where more important principal 
components are assigned greater weights); only variables with meaningful eigenvectors (e.g. >0.40) are presented. 
cCox regression using calculated Principal Component-Scores for each participant where the scores represent a linear algebraic 
combination of all variables included in the PCA model and weighted by eigenvectors.   
dAdjusted for HIV type (HIV-1 plus HIV-dual or HIV-2), age, gender, body mass index, absolute CD4 cell count (>500, 200 to 500, < 
200 cells/µL) at HIV diagnosis.  
eThe iron dysregulation index represents the combined impact on mortality of the variables in the principal component analysis-
identified patterns.  The observed concentrations measured for each iron and inflammatory variables were classified into tertiles 
whereby a value of 1 was assigned to the lowest hazard ratio (refer to Table 3.3). In these data, the lowest mortality was associated 
with the lowest tertile of hepcidin, ferritin, ACT and sTfR and the highest tertiles of transferrin, iron and hemoglobin.  All 
intermediate tertiles were assigned a value of 2; and all remaining tertiles were assigned a value of 3 (e.g. those associated with the 
greatest hazard ratio for mortality in Table 3.3).  Values were summed for each individual to represent an overall iron dysregulation 
index specific for each pattern. The iron dysregulation index was modelled as a single continuous variable using unadjusted and 
adjusted Cox regression.  
fThe index for PCA1.2 and PCA2.2 is equivalent because the same pattern of principal components (e.g. iron-sTfR-hemoglobin) was 
identified in both PCA models whether ACT was included or not 
g6-dimensional model including all iron homeostasis variables entered in tertiles 
h7-dimensional model including all iron homeostasis variables plus ACT entered in tertiles 
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Discussion 
This study characterizes hepcidin at the time of HIV diagnosis in relation to iron 
homeostasis, inflammation and all-cause mortality in men and women with HIV infection.  The 
findings demonstrate that hepcidin is integrally linked with the complex iron distribution that is 
associated with inflammation in HIV infection, a key cause of AI.  This study also provides the 
first indication that elevated hepcidin is a risk factor associated with mortality in HIV infection 
using unadjusted regression, though it is unclear whether the mechanism is mediated through 
its association with negative causes and/or consequences of inflammation, maladaptive iron 
distribution or a reason yet to be identified.   
While data regarding hepcidin in HIV infection remains limited, the findings from this 
study support those of an Indonesian study reporting serum hepcidin was positively correlated 
with ferritin, and inversely correlated with Hb and absolute CD4 cell counts (15).  Wisaksana et 
al. (15) also observed that elevated hepcidin at study entry was associated with an increased 
probability of starting tuberculosis treatment within one to two months. Increases in 
macrophage iron stored in ferritin due to elevated hepcidin expression in an already 
immunocompromised host may alter the host-pathogen competition for iron and increase 
susceptibility to macrophage-tropic pathogens like Mycobacterium tuberculosis.  While 
increased susceptibility to opportunistic infections like tuberculosis may explain in part the 
poorer mortality prognosis associated with elevated hepcidin in the current study (34), the 
unavailability of cause-specific mortality data prevents testing this hypothesis with these data. 
Additional possible mechanisms linking elevated hepcidin and increased mortality are 
presented in Figure 3.4.  The inverse association between hepcidin and absolute CD4 cells 
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observed in this study and others (15) suggests that elevated hepcidin may be attributable to 
advanced disease stage and corresponding elevated levels of inflammation. While increased 
hepcidin expression may be a consequence of inflammation, higher systemic hepcidin and the 
resulting transfer of iron from the bloodstream into macrophages may also contribute to HIV 
progression via enhanced HIV propagation and destruction of CD4 cells.  In an in vitro study, 
iron export by ferroportin in the absence of hepcidin was associated with decreased HIV-1 
transcription (14).  Adding hepcidin counteracted the iron efflux leading to increased 
intracellular iron and altered HIV production in CD4 cells and macrophages.   
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Figure 3.4. Pathways to HIV-associated anemia 
A complex combination of interdependent factors including viral replication, microbial translocation, CD4 cell depletion, and chronic 
immune activation has been proposed as the driving force behind HIV disease progression (35).  Production of pro-inflammatory 
cytokines (including IL-6) appears to both contribute to and also be dependent on factors driving disease progression, and in turn, 
stimulates hepcidin production and triggers the acute phase response.  As a result, there is an increase in hepcidin-mediated 
ferroportin degradation and characteristic shift in iron from the bloodstream to the macrophage that is characterized by decreased 
plasma iron, decreased hemoglobin, decreased transferrin, increased sTfR and increased ferritin ultimately resulting in HIV-
associated anemia.  While ART is known to resolve some (but not all) HIV-associated anemia, its role in the proposed pathway is 
currently unknown.  Alternatively, HIV-associated anemia may be the result of nutritional consequences of HIV and/or other (non-
HIV-related) causes of anemia.  Arrows indicate connected entities that are part of a pathway whereby solid arrows represent 
established pathways and dotted arrows remain hypothetical; lines ending without arrows indicate inhibition or blockage. 
sTfR=soluble transferrin receptor; ART=antiretroviral therapy 
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Hepcidin expression is regulated by inflammation (upregulation), erythropoiesis and 
hypoxia (downregulation) and hepcidin concentrations are correlated with iron homeostasis 
biomarkers (e.g. ferritin, transferrin), although the relative hierarchy and biological importance 
of each under normal and clinical circumstances remains to be established (26, 36-38).  By using 
statistical techniques designed to reduce redundancy of multiple correlated factors, further 
insight into the iron and infection relationship is possible.  In this study, PCA revealed two 
distinct patterns, each dominated by a different group of variables.  Given the specific variables 
statistically assigned to each pattern, it is possible to conceptually speculate that the first 
pattern is associated with inflammation (hepcidin-ferritin-transferrin, with or without ACT) and 
the second with erythropoiesis (iron-sTfR-Hb).  While both patterns may be influencing aspects 
of anemia and iron homeostasis, the regression analyses suggests that the inflammatory-
associated iron homeostasis pattern may be of greater relative importance in HIV.  An 
understanding of the possible hierarchical nature of factors mediating hepcidin expression has 
not been elucidated for any infection.  Early observations by Jonker and colleagues (37) suggest 
they are complex.  In a study of severely anemic Malawian children living in a region with high 
malaria and generalized infectious disease burdens, low hepcidin concentrations were observed.  
Since infection-induced inflammation was likely contributing to increased hepcidin expression, 
the very low hepcidin concentrations seems counterintuitive. They speculated that under 
conditions of severe anemia-associated hypoxia and resulting increased erythropoiesis, 
infection-associated inflammatory signals that usually upregulate hepcidin may be overridden 
or down-regulated.     
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At this time, guidelines for anemia intervention in global settings include screening for 
malaria, treating helminth infection and providing iron/folate supplements; however, self-
treatment using iron supplementation is common (39).  This study provides support that 
elevated hepcidin is associated with anemia, and given the link with inflammation; screening to 
distinguish the type of anemia (e.g. AI and/or IDA) would help to select the most appropriate 
anemia intervention.  Evaluation of Hb alone can determine neither the likely cause of anemia 
nor the best timing of interventions.  Hepcidin concentrations have been shown to predict non-
responsiveness to oral iron therapy (40), and in combination with other iron biomarkers such as 
ferritin and/or transferrin, hepcidin may guide in whom and when iron-based anemia 
interventions may be ineffective (27, 41, 42).  Many hepcidin interventions are in development 
including hepcidin antagonists mediating effects through inhibiting hepcidin production (e.g. 
anti-inflammatories like anti-interleukin-6/interleukin-6R, anti-tumor necrosis factor-α), 
neutralizing hepcidin peptides (e.g. anti-calins, anti-hepcidin monoclonal antibodies) or 
interfering with hepcidin–ferroportin binding (e.g. thiol modifiers, anti-ferroportin monoclonal 
antibodies) (43, 44).  While lowering hepcidin may be of benefit for iron homeostasis related to 
anemia, it could also negatively alter the host-pathogen competition for iron (37).  Iron 
supplementation during active infection may overcome the universal iron sequestration 
mechanism mediated by the innate immune response.  If this occurs while simultaneously 
intervening to lower hepcidin concentrations, a flood of iron dumped into the periphery could 
negatively alter the host-pathogen competition for iron (45), making infection control a 
prerequisite to iron-based anemia interventions. 
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The role of ART in mitigating hepcidin and iron homeostasis mechanisms remains to be 
elucidated (Figure 3.4), and the study is limited by the use of biological archives collected prior 
to widespread ART usage. While generalizability is limited to similar populations, the study 
findings have broad relevance as many people in developing countries present for HIV diagnosis 
with baseline characteristics similar to those in this study, others are diagnosed and lost to 
follow-up before ART is initiated and some drop-out of medical follow-up after ART initiation.  
For these groups, and as a reference for future studies seeking to identify and treat the 
subgroup of ART-treated individuals with residual or incident anemia (Table 3.1), the current 
data is important.  Medication usage (ongoing or newly initiated) around the time individual 
plasma samples was unknown, and should be considered for future studies.  Although these 
findings point to the importance of hepcidin in HIV infection, a portion of the statistical 
inferences were based on data-derived tertile categorizations of hepcidin and further research 
to identify clinically relevant cut-off points is needed.  Lastly, while elevated hepcidin was 
associated with mortality in unadjusted regression models, the association was not statistically 
significant in models adjusted for a number of known mortality covariates (e.g. CD4, BMI, 
gender, age).  Further studies may help to clarify the independent hepcidin association.       
In summary, hepcidin is a piece of the complex and dynamic relationship linking HIV-associated 
anemia, iron homeostasis, inflammation and mortality in HIV infection.  Higher hepcidin 
concentrations at HIV diagnosis are associated with a greater likelihood of mortality in men and 
women, and understanding how hepcidin evolves and influences iron homeostasis throughout 
early and chronic HIV infection is needed.  This is especially important as many people with HIV 
suffer from anemia before ART initiation, and since ART may not fully resolve inflammation or 
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anemia. Overall, this study provides additional insight for the development of effective 
evidence-based decisions to prevent and manage HIV-associated anemia and maladaptive iron 
homeostasis occurring at all stages of HIV infection. 
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Abstract 
Early identification of individuals at risk for progressing to active tuberculosis (TB) disease may 
limit new transmission and improve clinical outcomes.  Evidence indicates altered iron 
homeostasis may identify those at greater risk of disease progression in HIV co-infection.  We 
aimed to investigate iron homeostasis biomarkers as risk factors for progression to TB.  
Archived plasma samples were analyzed from household contacts of pulmonary TB index cases 
in The Gambia.  Contacts were classified as asymptomatic non-progressors (n=17) or TB-
progressors (n=10), which included two HIV-infected participants.  Iron homeostasis 
(hemoglobin, ferritin, hepcidin, soluble transferrin receptor, transferrin) was assessed in all 
contacts at study recruitment.  Plasma was collected a median of 910 days prior to TB diagnosis. 
Low transferrin around the time of known exposure to infectious TB was a disease progression 
risk factor for all TB-progressors (Poisson incidence rate ratio: 0.55; 95% CI:0.35-0.89).  Iron 
homeostasis also differed between early and delayed TB-progressors, with higher ferritin and 
hepcidin concentrations observed among early TB-progressors (mean ferritin 50.2 vs. 26.2 
ng/ml; P=0.027; mean hepcidin 37.7 vs. 5.6 ng/ml; P=0.036).  Iron homeostasis is associated 
with progression to TB among household contacts. Further studies are needed to elucidate 
mechanisms and determine the clinical utility of monitoring iron homeostasis biomarkers.  
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Introduction 
Progression from uninfected or latent tuberculosis infection to clinical tuberculosis (TB) 
disease is frequently asymptomatic or associated with only mild symptoms during the first few 
months of disease (1).  This can significantly delay diagnosis and treatment, resulting in higher 
TB mortality (2-4) and ongoing transmission (5, 6).  Indeed, treatment delays are considered an 
important contributor to the approximately 1.5 million deaths and 9.0 million new TB cases 
reported each year (7, 8).  Current approaches to reduce treatment delays include improved TB 
diagnostics (9) and active case finding strategies (10).  While these approaches are helpful (11-
13), identification of individuals at risk of disease progression could lead to further 
improvements.  
Altered host iron status has been previously identified as a risk factor for progression to 
TB among HIV-infected individuals (14, 15), and a number of studies have indicated that 
Mycobacterium tuberculosis (Mtb) iron acquisition plays an important role in TB pathogenesis 
(16-20).  A complex and intricate host-pathogen iron competition begins early in most 
infections.   In TB, immune recognition of Mtb by the human host induces a pro-inflammatory 
reaction that restricts Mtb iron access (16).  In response, Mtb manufactures siderophores, 
molecules capable of binding iron more strongly than host iron-storage proteins [reviewed in 
(21)].  Siderophore biosynthesis has been shown to be essential for Mtb growth and virulence 
(17, 19), suggesting that the success of Mtb in iron-scarce environments is due in part to its 
ability to acquire host iron.  Despite the toxicity associated with iron excess, Mtb appears to 
also thrive when iron availability is increased (16). High macrophage iron stores have been 
linked to an increased likelihood of contracting Mycobacterium spp. infections (22), and dietary 
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iron overload has been associated with an increased risk of developing pulmonary TB (PTB) (23) 
or dying from TB (24).   
 Only a minority of exposed or infected people ever progress to clinical TB disease 
during their lifetimes.  Among those that do progress, it typically occurs after a long clinical 
latency period.  This presents considerable challenges to studying TB susceptibility risk factors 
since biomarkers of TB susceptibility need to be collected prior to the initiation of disease 
pathogenesis.  As a result, biomarker studies require the prospective follow-up of large 
numbers of contacts of known infectious TB cases for a period of several years.  To overcome 
this obstacle, this case-cohort study was designed to investigate iron homeostasis biomarkers 
as risk factors for progression to TB using archived plasma samples that were obtained as part 
of a larger TB case-contact study.    
Methods  
Study participants and definitions 
Cryopreserved plasma and data from household contacts of PTB index cases recruited to 
the ongoing TB case-contact (TBCC) platform at the Medical Research Council Unit in The 
Gambia were used. The TBCC is a unique research platform designed to identify TB disease 
susceptibility risk factors in a large cohort of household contacts and has been described in 
detail elsewhere (25). Household contacts of index PTB cases were eligible to participate in the 
current case-cohort study if ≥15 years of age, maintained a shared residence with an index PTB 
case for ≥3 months prior to index case disease diagnosis and had a sufficient plasma sample 
archive for iron homeostasis analysis.  All eligible TB-progressors cases identified within the 
larger cohort were included, as well as a random selection of non-progressors.  In addition, TB-
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progressors and non-progressors were compared with a third group of culture-confirmed active 
PTB cases at TB diagnosis (Figure 4.1). Ethical approval for the TBCC platform was granted by 
The Gambian Government/Medical Research Council Unit joint ethics committees, and 
additionally, for this case-cohort study by Cornell University. 
 All participants had a Tuberculin Skin Test (TST) (2 tuberculin units of Purified Protein 
Derivative RT23, Staten Serum Institute, Denmark) and underwent a clinical evaluation that 
included a comorbidity assessment with TB-specific clinical questions.  Household contacts with 
symptoms consistent with TB were classified as “TB-progressors” if they developed active TB 
≥90 days after study enrollment or were classified as “non-progressors” if they did not have 
evidence of TB throughout the follow-up period (Figure 4.1).  TB-progressors were further 
categorized as “early TB-progressors” if they progressed to TB within two years of study entry 
or “delayed TB-progressors” if they developed TB after two years of follow-up.   
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Figure 4.1. Study Flowchart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
317 Index PTB Cases identified between 
2002 and 2004 through the Gambian 
Tuberculosis Case-Contact Study 
2353 Household TB Contacts 
63 TB-progressors 2290 TB non-progressors 
45 adult PTB cases identified 
between 2010 and 2012 
45 active TB cases 
12 excluded; 
prevalent TB 
diagnosis within 
90 days 
21 excluded; 
plasma 
unavailable 
10 TB-progressors 17 non-progressors 
1145 excluded; 
plasma 
unavailable 
Follow-up  
1128 excluded; 
<15 years of age 
20 excluded; 
<15 years of age 
TB=tuberculosis; PTB=pulmonary tuberculosis 
8 HIV-uninfected 
TB-progressors 
2 HIV-infected 
TB-progressors 
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Clinical and laboratory data 
Enrollment characteristics included data on age, gender, body mass index (BMI), HIV-
seropositivity, hemoglobin (Hb), white blood cell count and mean corpuscular volume (MCV).  
Plasma ferritin (Immuno-biological Laboratories, Germany), soluble transferrin receptor (sTfR) 
(R&D Systems, UK) and transferrin (Cygnus Technologies, USA) were measured by ELISA. 
Hepcidin was measured using a competitive enzyme immunoassay (Bachem, USA).  All assays 
were optimized for use with plasma, and test samples, standards and controls were assayed in 
duplicate and concentrations interpolated from 4-parameter logistic standard curves (log/log 
curves for sTfR).  All standard curves were generated using SoftmaxPro 6 (Molecular Devices, 
USA).  Samples with an intra-assay coefficient of variation >15%, were re-assayed.  Lower limits 
of detection for all assays, with the exception of hepcidin, were defined by the manufacturer.  
For hepcidin, the limit of detection (0.02 ng/ml) was interpolated at three standard deviations 
from the all plate mean (e.g. wells that contained diluent in lieu of hepcidin standard or sample).  
Statistical Analysis  
Median values of biomarkers and clinical measurements with non-normal distributions 
were compared using the Mann-Whitney U-test.  Unpaired Student’s t tests were similarly used 
for normally distributed biomarkers and measurements as well as comparisons of small 
samples. Chi-square tests were used to compare frequency distributions. Since median and/or 
mean concentrations of ferritin, sTfR and hemoglobin fell within normal clinical reference 
ranges, and a reference range for hepcidin has not yet been defined, iron homeostasis 
biomarker concentrations were standardized and modeled continuously.  Univariate 
associations between standardized iron biomarkers and the binary outcome of “TB progression” 
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or “no TB progression” were assessed using Poisson regression with robust variance estimates.  
Poisson regression is considered an alternative to log-binomial regression when outcomes are 
common and odds ratios cannot be interpreted as relative risks (26).  Given the mixed HIV-
status of the TB-progressor group, all analyses were run in parallel with two groups of TB-
progressors:  one inclusive of the two HIV-seropositive individuals, the other excluding them.  
Examination of iron homeostasis biomarker concentrations (hemoglobin, ferritin, hepcidin, 
soluble transferrin receptor, transferrin) and clinical characteristics (BMI, MCV, white blood 
cell) suggested that HIV-infected TB-progressors were not statistically or clinically different 
from HIV-negative TB-progressors in measured risk factors.  However, since the absolute CD4 
cell counts were unknown and because HIV infection is known to be a strong risk factor for TB 
progression, the results of both the HIV-inclusive and HIV-exclusive analyses are presented. 
Statistical analyses were performed using STATA 13.0 (College Station, TX USA) and Prism 6.0 
(La Jolla, CA USA).   
Results  
Demographic and clinical characteristics of the TBCC platform, the case-cohort 
subsample drawn from the TBCC platform and the active TB cases are summarized in Table 4.1.  
Overall, the case-cohort subsample was representative of the larger TBCC platform as 
participants were not significantly different based on age, gender, BMI, white blood cell and 
MCV.  The median time to progression for all case-cohort TB-progressors was 910 days 
[interquartile range (IQR): 470 to 1337 days, n=10], and slightly longer at 1047 days (IQR: 611 to 
1426, n=8) among TB-progressors who were HIV-negative.  Early case-cohort TB progressors 
were diagnosed at approximately one year following study entry, and this did not differ 
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according to HIV-seropositivity, while delayed progressors were diagnosed at a median of 3.2 
years.  Known TB risk factors like age, gender and HIV status were not statistically different 
between TB-progressors, non-progressors or active TB cases.   While BMI did not differ 
between TB-progressors and non-progressors, TB cases had significantly lower BMI and MCV 
and higher white blood cells.  Additionally, significant differences were not detected in the 
comparison between TB-progressors when grouped with or without the two HIV-seropositive 
TB-progressors.   
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Table 4.1. Enrollment characteristics of age-eligible TB-progressors and non-progressors from the Medical Research Council TB Case-
Contact (TBCC) platform (n=1193), TBCC subjects with available plasma samples (n=27) and among active tuberculosis cases prior to 
treatment initiation (n=45) 
 
 
  TB case-contact (TBCC) platform 
(e.g. source cohort) 
Case-cohort subsample of TBCC platform 
 
Active TB 
cases, prior to 
treatment 
initiation 
 Non-progressors 
(n=1162) 
TB-progressors  
(n=31) 
Non-progressors 
(n=17) 
TB-progressors 
(HIV+ and HIV-)  
(n=10) 
TB-progressors 
(HIV- only) 
(n=8) 
n=45 
Age, years 25 (20 to 36) 26 (21 to 42) 28 (20 to 39) 
 
27 (19 to 30) 26 (19 to 28) 29 (23 to 38) 
Female, % 58% (671/1162) 55% (17/31) 47% (8/17) 50% (5/10) 38%(3/8) 38% (17/45) 
HIV-infected, % 4% (39/1051) 13% (4/31) 0% (0/17) 20% (2/10) 0% (0/8) 4% (2/45) 
Time to TB diagnosis (days)  
         All TB-progressors N/A 718 (436 to 
1169) 
N/A 910 (470 to 
1337) 
1047 (611 to 
1426) 
N/A 
         Early TB-           
progressors 
N/A 437 (151 to 607) N/A 386 (167 to 677) 352 (150 to 553) N/A 
        Delayed TB-
progressors  
N/A 1169 (1035 to 
1401) 
N/A 1175 (973 to 
1535) 
1175 (973 to 
1535) 
N/A 
Body mass index (kg/m2) 21.6 ± 4.6 
(n= 1153) 
20.3 ± 3.3  
(n=30) 
21.1 ± 3.3 19.9 ± 2.4  
(n=9) 
19.8 ± 2.7 (n=7) 18.1 ± 2.1*#  
(n=44) 
White blood cell count  5.6 ± 1.83  
(n=1026) 
5.0 ± 1.4  
(n=28) 
5.2 ± 1.5  
(n=16) 
4.8 ± 1.2  
(n=8) 
4.8 ± 1.3 (n=7) 7.2 ± 2.6*#  
(n=39)  
 
Mean corpuscular 
volume (fL) 
84.9 ± 7.7  
(n=1026) 
82.6 ± 7.5  
(n=28) 
83.4 ± 6.9  
(n=16) 
84.5 ± 5.1  
(n=8) 
84.4 ± 5.4 (n=7) 80.2 ± 7.6*# 
(n=39) 
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sTfR=soluble transferrin receptor; PTB, pulmonary tuberculosis; TB=tuberculosis; TBCC=Gambian TB Case-Contact study 
Data are presented as median (IQR) or mean ± standard deviation, % (n/n).  When missing data occurred, the sample size is 
indicated in the table. 
There were no significant differences between: 
-TB-progressors in TBCC compared to TB-progessors in the TBCC subjects with available plasma 
-Non-progressors in TBCC compared to non-progessors in the TBCC subjects with available plasma 
-TB-progressors and non-progressors in the TBCC subjects with available plasma only 
Statistical differences were assessed using Student’s t tests for normally distributed variables and Mann-Whitney U-tests for non-
normally distributed variables; Chi-Squared tests were used to compare frequencies. 
* Significantly different (P<0.05) when active TB cases compared to non-progressors from TBCC or the TBCC subjects with available 
plasma. 
# Significantly different (P<0.05) when active TB cases compared to TB-progressors from TBCC or the TBCC subjects with available 
plasma 
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 A dose-response relationship for concentrations of iron homeostasis biomarkers in non-
progressors, early or delayed TB-progressors and active TB is shown in Figure 4.2. The lowest 
transferrin concentrations and highest hepcidin or ferritin concentrations were observed in 
active TB cases, followed by early TB-progressors, delayed TB-progressors and lastly, non-
progressors.  Each iron homeostasis biomarker had statistically significant associations within 
this pattern, but not all comparisons within the sequence were statistically significant.   Earlier 
TB progression appears to be linked to significantly higher concentrations of hepcidin (p=0.036) 
or ferritin (p=0.027) compared to delayed TB-progressors among all TB-progressors.  The 
direction and magnitude of effects were similar when including or excluding the two HIV-
seropositive TB progressors, however the associations were no longer statistically significant. 
While a reference range has not yet been established for hepcidin, median/mean values 
of plasma ferritin, sTfR and Hb were within the normal reference ranges established for iron 
status.  Only mean transferrin concentration was below normal (27) in early and delayed TB-
progressors and also in active TB cases (Figure 4.2).  Lower transferrin was associated with a 
greater likelihood of incident TB [all TB-progressors Incidence Rate Ratio (IRR): 0.55; 95% 
confidence interval (CI): 0.35 to 0.89] (Table 4.2).  Excluding the two HIV-infected TB-
progressors from analysis did not change the magnitude or direction of effect; however, the 
confidence interval increased and the association was no longer statistically significant.  
Although not statistically significant, an IRR greater than 1.00 indicated that higher hepcidin 
was associated with a greater probability of progression to TB (IRR: 1.27), and an IRR below 
1.00 suggested that higher BMI was associated with a lower probability (IRR: 0.75).    
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Figure 4.2 Iron homeostasis at enrollment among active tuberculosis cases prior to treatment 
initiation and household contacts that became early TB-progressors (3 to 24 months), delayed 
TB-progressors (24 to 48 months) or remained non-progressors   
TB=tuberculosis; (HIV+)=HIV-infected; (HIV-)=HIV-uninfected 
Early and Delayed TB-progressors (HIV+ and HIV-) includes HIV-infected TB-progressors (n=2); 
these HIV-infected TB-progressors were excluded in Early and Delayed TB-progressors (HIV-
only).   
Shaded area represents the normal reference range established for ferritin, soluble transferrin 
receptor, transferrin and hemoglobin (27).  Parallel dotted lines at hemoglobin=12 g/L and 
hemoglobin=13 g/L represent the lower cutoffs for normal hemoglobin in women and men 
respectively (28).  The hepcidin box does not have a shaded area since there is no established 
reference range. 
P-values <0.10 are noted, and were determined using unpaired Student’s t-tests (for 
comparisons between normally distributed samples) and Mann-Whitney U tests (for 
comparisons between non-normally distributed samples). 
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Table 4.2. Poisson regression models of the association between standardizeda iron homeostasis biomarkers, standardized body 
mass indexa and progression to pulmonary tuberculosis  
 All TB-progressors included Only HIV-negative TB-progressors included 
 TB-progressors/ 
non-progressors  
Incidence rate ratio  
(95% CI) 
P-value TB-progressors/ 
non-progressors 
Incidence rate ratio  
(95% CI) 
P-value 
Transferrin  10/17 0.55 (0.35 to 0.89) 0.015 8/17 0.58 (0.31 to 1.10) 0.096 
Hepcidin 10/17 1.27 (0.86 to 1.87) 0.226 8/17 1.11 (0.65 to 1.89) 0.713 
Ferritin 10/17 0.98 (0.63 to 1.51) 0.913 8/17 0.78 (0.49 to 1.31) 0.373 
Soluble transferrin receptor 10/17 0.99 (0.65 to 1.53) 0.982 8/17 1.09 (0.71 to 1.71) 0.672 
Hemoglobin 9/16 1.20 (0.68 to 2.13) 0.526 7/16 1.37 (0.71 to 2.62) 0.351 
Body mass index  9/16 0.75 (0.43 to 1.31) 0.317 7/16 0.72 (0.36 to 1.43) 0.352 
 
CI=confidence interval 
 
aAll biomarkers have been rescaled with mean=0; standard deviation=1. 
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Discussion  
Findings from this study suggest that iron homeostasis is linked to TB progression in 
household contacts of infectious TB cases.  TB progression at any time point was associated 
with reduced baseline concentrations of transferrin, and early TB-progressors had higher 
baseline concentrations of ferritin and hepcidin when compared with delayed TB-progressors.  
The study findings are consistent with a hypothesized functional role for iron in TB 
pathogenesis.  Moreover, monitoring iron homeostasis biomarkers in TB contacts may be a 
useful indicator, in conjunction with other early-onset biomarkers, to identify individuals at 
greater risk for progression to TB.   
These observations are largely consistent with animal and in vitro studies linking 
addition of iron to increased Mtb growth (16), and also with evidence indicating elevated 
ferritin and hepcidin along with decreased transferrin and hemoglobin, are risk factors for 
incident TB in a Gambian HIV-seropositive cohort (14, 15).  They also add to compelling 
evidence for a role for iron in TB pathogenesis.  Specifically, our data support a hypothesis in 
which increased access to iron for Mtb siderophores leads to improved success for the 
pathogen.  At the crux of this hypothesis is the hypothesis that ‘too much iron’, or likely too 
much iron sequestered in macrophages as ferritin or bound to circulating transferrin, leads to 
increased TB susceptibility via improved efficiency of Mtb iron acquisition.  Host-acquired iron is 
a co-factor for proteins involved in vital Mtb cellular processes including respiration, electron 
transport, DNA replication, and stress resistance. Varying levels of iron within the Mtb-occupied 
phagosome influences the activity of the Mtb iron-dependent regulators furA, furB, SirR and 
IdeR.  These regulators promote and repress the transcription of certain Mtb genes including 
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the oxidative stress response protein katG, the iron storage proteins bfrA and bfrB and the 
protein machinery involved siderophore biosynthesis (reviewed in (21)).  Mtb siderophores 
access multiple host iron sources including ferritin and transferrin (29), are essential for Mtb 
virulence (19) and are capable of increasing iron availability in the mycobacterial phagosome 
almost 20-fold (30).  In an iron-limited environment the Mtb iron dependent regulator IdeR 
promotes siderophore biosynthesis in human macrophage-like THP-1 cells (31).  Conversely, in 
the presence of sufficient iron, IdeR represses siderophore biosynthesis (in culture) and 
positively regulates synthesis of the iron storage protein bfrA (31).  The latter suggests a 
possible effort by Mtb to redistribute limited resources away from iron acquisition under 
conditions of iron sufficiency and implies that increased efficiency of iron acquisition could lead 
to greater Mtb success. Our findings are consistent with a scenario in which increased access to 
ferritin (possibly due to hepcidin-mediated macrophage iron retention) and saturated 
transferrin for Mtb siderophores improves the efficiency of iron-acquisition and creates an 
opportunity for Mtb to shift resources toward growth and progression to active TB disease.  If 
evidence from future studies lend support to this hypothesis, investigations into mechanisms 
that influence Mtb siderophore production and activity as well as host iron storage and 
transport, including the role of transferrin polymorphisms (32), may be warranted.   
The ability to identify who is at risk for transitioning from an infected and stable state to 
an infected but disease progressing state is critical for both the clinical management of the 
individual and for the prevention of TB transmission at the population level.  While the current 
study aimed to make this identification from the iron homeostasis biomarker perspective, 
previous efforts in The Gambia and elsewhere have focused on the demographic, clinical, 
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microbiological, immunological and genetic perspectives. Known household exposure to TB, 
smoking and ethnicity increased the likelihood of active TB disease in a Gambian case-control 
study (33). In Uganda, a case-contact study identified both young children and HIV-infected 
individuals as being particularly vulnerable to TB progression (34).  From the microbiological 
perspective, analysis of Mycobacterial lineage in The Gambia suggested that pathogen 
differences influence progression to active TB (35).  Also, in The Gambia, previous analysis of 
TB-progressors and non-progressors from the TBCC platform indicated that progressors tended 
to have increased levels of the cytokine IL-18, decreased expression of the anti-apoptotic gene, 
Bcl2 and increased expression of the gene encoding CCR7(36).   Combined with the results from 
the current study, these previous findings suggest that strategic monitoring of individuals prior 
to TB diagnosis may be useful in identifying who is at risk for progression to TB.   
Importantly, while the findings from the current study indicate that monitoring iron 
status, and in particular, transferrin, ferritin and hepcidin, may be useful in identifying who is at 
risk of TB progression, the described pattern of biomarkers would not be identified during 
routine screening for iron status. Only Hb is routinely measured in a clinical setting, and Hb, as 
well as sTfR and ferritin concentrations were within normal ranges (27).  A reference range for 
hepcidin has not been established.  Further studies are warranted to determine if the pattern of 
iron biomarker concentrations identify TB susceptibility, and if so, determine TB-specific versus 
anemia or iron-status thresholds or cutoffs.  
A major strength of this study is its unique design, which presented a rare opportunity 
to investigate biomarkers as risk factors for susceptibility to TB rather than as factors associated 
with TB diagnosis or prognosis.  However, the findings must also be considered in the context of 
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the study limitations.  The number of TBCC participants with available plasma samples was 
small and restricted to a mixture of HIV-infected and HIV-uninfected individuals.  The small 
sample size also precluded subgroup analyses according to HIV status, and full consideration of 
potential confounding/modifying variables like age, smoking status, BMI and contact proximity 
to the index PTB case.  Further studies will be needed to further clarify and confirm the key 
study observations.   
Conclusions 
The probability of TB progression following infection appears to be linked to a distinct 
pattern of iron homeostasis biomarkers.  This pattern is representative of perturbations in iron 
homeostasis that are consistent with a plausible biological mechanism leading to TB 
progression, but would not be identifiable in routine assessment of iron status that typically 
includes Hb.  Targeted monitoring of iron homeostasis biomarkers in TB contacts may help to 
identify those at greater risk for progression to TB, thereby reducing delays in TB diagnosis 
and/or treatment to improve TB-related health outcomes and decrease TB transmission.   
Further studies are needed to validate the mechanistic links between these biomarkers and 
HIV-associated and non-HIV-associated TB pathogenesis, and to determine if iron homeostasis 
biomarkers do indeed have clinical utility.  
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Abstract  
Background: Anemia is common in tuberculosis and multiple etiologies necessitate targeted 
interventions.  The proportion of iron-responsive anemia due to iron deficiency compared to 
iron-unresponsive anemia due to impaired iron absorption/redistribution from tuberculosis-
associated immune activation or inflammation is unknown.  This impedes selection of safe and 
effective treatment and appropriate intervention timing.  
Methods: Baseline hemoglobin, ferritin, hepcidin, soluble transferrin receptor (sTfR) and 
transferrin were measured in 45 confirmed pulmonary tuberculosis cases, 47 tuberculin skin 
test (TST)-positive controls and 39 TST-negative controls in The Gambia. TB cases were 
additionally followed two and six months after tuberculosis treatment initiation.  Mutually 
exclusive anemia categories based on iron biomarker concentrations were iron-deficiency 
anemia (IDA), anemia of inflammation (AI) and multifactorial anemia (IDA+AI). 
Results: Anemia was more frequent in tuberculosis cases (67%) compared to TST-positive (36%) 
or TST-negative (21%) controls. AI was the predominant anemia at tuberculosis diagnosis, 
declining from 36% to 8% after six months of treatment; however, a corresponding reduction 
was not evident for anemia with iron-responsive components (IDA, IDA+AI).  Iron biomarkers 
discriminated between active tuberculosis and TST-positive or TST-negative controls, as well as 
between active untreated and treated tuberculosis.  This was most noticeable for hepcidin, 
which decreased from a median of 84.0 ng/ml at diagnosis to 9.7 ng/ml after two months 
(p<0.001).   
Conclusions: Tuberculosis chemotherapy is associated with significant reductions in AI but IDA 
and IDA+AI remain unresolved.  Iron-based interventions are needed for IDA and IDA+AI, and 
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monitoring iron biomarkers reveals a window for intervention opening as early as two months 
into tuberculosis treatment. 
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Introduction 
Anemia affects a quarter of the world’s population (1), and sub-Saharan Africa is 
disproportionately burdened (2).  Like all clinical conditions, resolution requires effective 
interventions to appropriately address etiologies.  Anemia results from a number of causes 
acting alone or in combination (2), however, untangling the causative factors in order to 
effectively target anemia interventions is rarely conducted in resource-restricted regions.  
These challenges contribute to the sustained high level of global anemia.   
Iron-based interventions are effective in treating iron-deficiency anemia (IDA) (3-5), but 
ineffective (6), unnecessary (7) and potentially unsafe (8, 9) when anemia of inflammation (AI) 
due to infection is present.  Providing sufficient dietary iron to meet iron requirements will 
resolve an iron supply problem (i.e. iron-responsive anemia), but will not resolve an iron 
delivery problem where absorbed dietary iron is blocked from release from intestinal 
enterocytes and body iron is shuttled to and retained in the macrophage.  This iron delivery 
problem is a hallmark of AI (i.e. iron non-responsive anemia) that requires resolution of the 
underlying infectious or inflammatory pathology (10).   Regions with high dual burdens of 
infectious diseases and malnutrition present a particular challenge in identifying when and how 
to treat existing anemia given that AI and IDA require such different interventions.  This 
challenge is especially salient in sub-Saharan Africa, where a mixture of multifactorial IDA+AI 
anemia may constitute more than 50% of anemia (2).   
Anemia is a common comorbidity at tuberculosis (TB) diagnosis, with prevalence 
estimates ranging from 32% to 86% (11-16).  While not specifically investigated, a large 
proportion of tuberculosis anemia is likely due to AI.  This is supported by data from two Asian 
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studies where the prevalence of anemia at TB diagnosis fell by 67 and 88% upon completion of 
TB chemotherapy without additional iron-based anemia interventions (14, 15).  While this is an 
important reduction in overall anemia, there were still a considerable number of participants 
with unresolved anemia by the end of TB treatment (19.9 and 7.6%, respectively), suggesting 
IDA or multifactorial IDA+AI was also present at TB diagnosis.    
Given the consequences of unresolved anemia in general (17-20), evidence pointing to a 
relationship between anemia, iron redistribution and TB susceptibility (21, 22) and reports 
linking anemia to poor clinical prognoses and mortality after TB diagnosis (16, 23, 24), further 
understanding of anemia management in TB is needed. Thus, this study was designed to: 1) 
characterize the relative contributions of anemia with iron-responsive components (IDA, IDA + 
AI) and iron non-responsive components (AI) to inform selection of the most appropriate 
treatment approach; 2) evaluate the evolution of biomarkers of iron status during TB therapy to 
identify the best timing of targeted anemia interventions in TB; and 3) investigate risk factors 
for TB anemia in The Gambia.   
Methods  
Adult participants were recruited following written informed consent as part of the 
ongoing TB Case-Contact study at the Medical Research Council Unit in The Gambia (25).  45 
culture-confirmed Pulmonary TB cases and 86 Mycobacterium tuberculosis Complex (MTBC)-
exposed contacts were recruited between October 2010 and May 2012, and cases were 
followed until completion of TB treatment. Tuberculin skin tests (TST) were performed to 
determine the infection status of all contacts using two tuberculin units (TU) of purified protein 
derivative (PPD).  An induration >10mm was considered TST-positive (n=47) and ≤10mm TST-
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negative (n=39) due to Bacille-Calmette Guerin (BCG) vaccination and high prevalence of 
environmental mycobacteria in this setting.  Sputum samples were stained with auramine and 
the Ziehl-Nielsen method. Sputum was decontaminated using N-acetyl cysteine (NALC)-NaOH 
before culturing in Bactec vials (Becton Dickinson, USA) and on paired Lowenstein-Jensen 
slopes. Positive cultures were confirmed by Ziehl-Nielsen smear.  
All TB cases underwent a clinical assessment at recruitment (defined as TB diagnosis) 
and at two and six months following TB treatment initiation. The clinical assessment included 
determination of disease severity by chest x-ray, comorbidity assessment and TB-specific 
clinical questions such as the presence of side pain, cough duration and weight loss.  Malaria 
screening was conducted using a rapid diagnostic test, and those with malaria were excluded 
from participation.  Blood samples were obtained from TB cases at all three time points and at 
baseline only for TST-positive and TST-negative groups with storage at -70oC until analysis.   At 
the time these data were collected, TB treatment success rate in The Gambia was >85% (26) 
and national TB treatment guidelines included an intensive phase of isoniazid, rifampicin, 
ethambutol, and pyrazinamide for two months followed by isoniazid and rifampicin for four 
months (27).   
Demographic, Anthropometric and Clinical Characteristics  
Data was collected on participant age, gender, body mass index (BMI), mid-upper arm 
circumference (MUAC), HIV-status, hemoglobin (Hb), white blood cell count (WBC) and mean 
corpuscular volume (MCV).   
Iron Status Biomarkers and Anemia Classification 
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Plasma or serum ferritin (Immuno-biological Laboratories, Germany), soluble transferrin 
receptor (sTfR) (R&D Systems, UK) and transferrin (Tf) (Cygnus Technologies, USA) were 
measured by ELISA. Hepcidin was measured using a competitive enzyme immunoassay 
(Bachem, USA). All biomarker assays were optimized for use with plasma and serum and a 
sensitivity analysis confirmed specimen type did not affect interpretation.  Test samples, 
standards, and controls were assayed in duplicate and concentrations interpolated from 4-
parameter logistic standard curves (log/log curves for sTfR).  All standard curves were 
generated using SoftmaxPro 6 (Molecular Devices, USA).  Samples with an intra-assay 
coefficient of variation >15%, were re-assayed.  Lower limits of detection (LoDs) for all assays, 
with the exception of hepcidin, were defined by the manufacturer.  For hepcidin, the LoD (0.2 
ng/ml) was interpolated at three standard deviations from the all plate mean (e.g. wells that 
contained diluent in lieu of hepcidin standard or sample). Anemia was defined according to 
World Health Organization criteria for males Hb <13 g/dL and females Hb <12 g/dL (28), while 
iron deficiency was defined as MCV <80 fL (29).  Anemia classification was based on mutually 
exclusive criteria as follows: 1) AI was defined as anemia plus sTfR/log(ferritin) ratio <14 (30); 2) 
IDA was defined as anemia plus iron deficiency without AI; and 3) IDA+AI was defined as IDA 
plus AI.   
Statistical Analysis 
Statistical analyses were performed using STATA 13.0 (College Station, USA) and Prism 
6.0 (La Jolla, USA). Median values of each biomarker were compared using the Wilcoxon 
matched pairs signed rank test for non-parametric comparisons at different time points (for 
cases only) and the Mann-Whitney U-test for comparisons of non-matched subjects (cases 
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compared to TST-positive and TST-negative contacts).  Paired and unpaired Student’s t tests 
were similarly used for normally distributed variables at different time points and for non-
matched subjects, respectively. Chi-square and Fisher’s Exact tests were used to compare 
categorical variables.  Logistic regression was used to model the relationships between disease 
status, iron parameters and the binary variables of anemia, IDA, AI and IDA+AI in a cross-section 
of the data that included TB cases, TST-positive and TST-negative data at baseline. Random-
effects multi-level logistic modeling to account for repeated observations within individuals was 
used to examine relationships between binary variables of anemia, IDA, AI, IDA+AI and iron 
biomarkers with disease-related variables including treatment duration and disease 
radiographic severity among the TB cases during TB treatment.  Multiple imputed values for 
anemia, IDA, AI and IDA+AI were included in the multi-level logistic regression model. Missing 
data followed a monotone-missing pattern indicating the absence of a value for one variable 
implied missing values for another variable. Imputation was performed as a sequence of 
univariate (conditional) imputation tasks, covariates included in the imputation models were: 
age, gender, BMI, MUAC, hepcidin, sTfR, ferritin and Tf. Participants with confirmed HIV 
seropositivity were antiretroviral naive and their disease stage or absolute CD4 cell count was 
unavailable.  HIV status was unconfirmed for 32 participants, and to determine the effect on 
these data, a sensitivity analysis was conducted.   Two extreme considerations were examined 
where all individuals with unknown HIV status were coded as “HIV positive” and then all as “HIV 
negative”.  Differences in interpretation including direction of effect, magnitude or statistical 
significance were not evident, and additionally, including only those individuals with confirmed 
HIV status (e.g. confirmed HIV-positive and confirmed HIV-negative) in models did not indicate 
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HIV infection was a significant confounder in these data.  Based on these analyses, HIV status 
was not included as an independent variable in final regression models.   
Results   
Characteristics of TB cases and contacts are summarized in Table 5.1. As expected, TB 
cases were experiencing significantly poorer health at TB diagnosis based on nutritional (lower 
BMI, MUAC), hematological (lower Hb and higher WBC) and iron status (higher ferritin, hepcidin, 
sTfR and lower Tf) parameters compared to TST-positive or TST-negative contacts (Table 5.1).  
Classification of anemia may inform anemia treatment in TB 
All-cause anemia was a common problem diagnosed in many study participants (41%, 
n=51/125).  AI accounted for 45% (n=23/51) of anemia amongst all participants (combined TB, 
TST-negative, TST-positive) and it was the most common anemia classification at TB diagnosis 
with more than 1/3 of TB cases experiencing AI (36%, n=14/39) (Table 5.1). While TB cases were 
significantly more likely to have AI at diagnosis than TST-negative/TST-positive combined (36% 
vs. 21%, respectively, p=0.002), the proportions of participants with IDA (18% vs. 12%, 
respectively, p=0.40) and IDA+AI (13% vs. 7%, respectively, p=0.32) were not significantly 
different (Table 5.1).   
Risk factors associated with all-cause anemia and cause-specific anemia including IDA, AI 
and IDA+AI in TB cases at diagnosis and contacts (TST+ and TST-) are summarized in Figure 5.1.  
AI, but not IDA or IDA+AI, was significantly associated with TB in a logistic regression model, 
indicating that AI was an important contributor to the observed association between TB and all-
cause anemia at diagnosis.  
Longitudinal assessment of TB anemia summarized in Table 5.2 indicated that TB 
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treatment for six months was associated with a significantly lower likelihood of all-cause 
anemia (adjusted OR=0.35, 95% CI=0.14 to 0.86), as well as AI (adjusted OR=0.19, 95% CI=0.06 
to 0.67) compared to TB diagnosis. In contrast, TB treatment was not associated with anemia 
resolution if baseline anemia had an iron-responsive component classified as IDA or IDA+AI at 
TB diagnosis (Table 5.2). 
Iron status biomarkers change significantly during TB treatment 
At TB diagnosis, concentrations of iron biomarkers in TB cases differed significantly from 
TST-positive and TST-negative contacts (Table 5.1, Figure 5.2) and changed considerably 
throughout TB treatment (Figure 5.3). Concentrations of ferritin, hepcidin and sTfR were found 
to be significantly higher in active but untreated TB cases at TB diagnosis compared to TST-
negative and TST-positive contacts combined, while concentrations of Tf and hemoglobin were 
significantly lower (Figure 5.2).  Ferritin, hepcidin and sTfR were significantly lower following 
two months of TB treatment (Figure 5.3), and no longer statistically different from TST-negative 
contacts after six months of TB treatment (Table 5.1).  Tf and hemoglobin concentrations 
increased during treatment to levels that were not statistically different from TST-negative 
contacts (Table 5.1 and Figure 5.3). A similar pattern was evident in a random-effects multi-
level logistic regression model adjusted for age and sex. The odds of elevated ferritin (OR=0.02, 
95% CI=0.003 to 0.17), elevated hepcidin (OR=0.03, 95% CI= 0.006 to 0.18), elevated sTfR 
(OR=0.15, 95% CI=0.03 to 0.71) and low Tf (OR=0.23, 95% CI=0.07 to 0.71) were significantly 
lower after two months of treatment vs. diagnosis, and after 6-months vs. diagnosis (elevated 
ferritin: OR=0.019, 95% CI=0.002 to 0.16; elevated hepcidin: 0.075, 0.02 to 0.31; elevated sTfR: 
0.11, 0.02 to 0.54; low Tf: 0.11, 0.03 to 0.39).  
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Table 5.1. Participant characteristics amongst Mycobacterium tuberculosis Complex-infected (TST-positive) and uninfected (TST-
negative) contacts at study recruitment and amongst TB cases at TB diagnosis and following two and six months of TB treatment  
 TST-negative 
n=39  
TST-positive 
n=47  
TB at diagnosis, n=45 TB at 2-months, n=43  TB at 6-months, n=44  
Age, years   23 (20 to 30) 28 (24 to 47) 29 (23 to 38) 
male, %  46% (18/39) 49% (23/47) 62% (28/45) 
HIV-negative, % 80% (31/39) 51% (24/47) 89% (40/45) 
HIV-positive, % 2% (1/39) 2% (1/47)  4% (2/45) 
HIV-unknown, % 18% (7/39) 47% (22/47) 7% (3/45) 
Nutritional status indicators  
 Body mass index 
(BMI) (kg/m2)* 
20.6 (18.9 to 
23.9) (n=37) 
22.2 (20.3 to 
24.5) (n=46) 
18.1 ± 2.1 (n=44) 19.2 ± 2.2 (n=39) 20.1 ± 2.0 (n=19) 
Mid-upper arm 
circumference 
(MUAC) (cm)* 
26.0 (24.9 to 
28.3) (n=38) 
26.5 (25.0 to 
28.0) (n=46) 
23.1 ± 2.2 (n=44) 24.5 ± 2.5 (n=43) 25.0 ± 2.2 (n=24) 
Hematological indicators   
Hemoglobin (Hb) 
(g/dL)* 
13.3 (12.5 to 
14.8) 
13.2 (11.5 to 
14.4) 
11.8 ± 2.0 (n=39) 12.6 ± 2.2 (n=7) 13.4 ± 1.7 (n=41) 
White blood cell 
count (WBC)* 
5.5  ± 1.2 5.6 (4.7 to 6.6) 6.9 (5.3 to 8.6) (n=39) 4.8 ± 0.6 (n=7) 5.2 ± 1.5 (n=41) 
Mean corpuscular 
volume (MCV) (fL) 
83.8 (81.3 to 
87.2) 
80.9 ± 8.1 80.2 ± 7.6 (n=39) 81.7 ± 6.4 (n=7) 82.3 ± 8.2 (n=41) 
Iron indicators  
Ferritin (ng/ml)* 21.9 (11.4 to 
39.0) 
36.4 (8.9 to 
62.1) 
164.5 (95.7to 252) 24.0 (9.1 to 76.3)  29.2 (11.6 to 89.2) 
Hepcidin(ng/ml)* 22.9 (5.9 to 
41.7) 
24.1 (2.4 to 
45.4) 
84.0 (43.8 to 145) 9.7 (3.9 to 53.0)  20.4 (2.5 to 65.1) 
Transferrin (g/L)* 1.8 (1.5 to 2.3) 1.9 (1.5 to 2.1) 1.2 ± 0.38 1.5 (1.1 to 2.0)  11.9 ± 0.63 
sTfR (nmol/L)* 18.5 (15.6 to 
22.0) 
23.2 (16.7 to 
27.2) 
29.36 (23.7 to 37) 24.1 ± 11.6 24.7 (19.1 to 31.2)  
  104 
Iron deficiency and anemia classification 
Iron Deficiency# 23% (9/39) 45% (21/47) 51% (20/39) 43% (3/7) 34% (14/41) 
Anemia# 21% (8/39) 36% (17/47) 67% (26/39) 57% (4/7) 41% (17/41) 
AI# 8% (3/39) 13% (6/47) 36% (14/39) 29% (2/7) 8%  (4/40) 
IDA 5% (2/39) 17% (8/47) 18% (7/39) 14% (1/7) 18% (7/40) 
IDA+AI 8% (3/39) 6% (3/47) 13% (5/39) 14% (1/7) 15% (6/40) 
Values are reported as median (IQR), mean ± SD, or % (n) 
IQR= interquartile range; n= sample size; MUAC= mid-upper arm circumference; Hb= hemoglobin; WBC= white blood cells; MCV= 
mean corpuscular volume; BMI=Body Mass Index; sTfR= soluble transferrin receptor; AI= Anemia of Inflammation; IDA= iron 
deficiency anemia  
 
Anemia= male Hb <13 g/dL, female Hb <12 g/dL 
Iron deficiency= MCV <80 fL  
AI= individuals who are anemic plus have an sTfR/log(ferritin) index < 14  
IDA= individuals who are anemic plus iron deficient, but were not classified as AI 
IDA+AI= individuals who are IDA plus have an sTfR/log(ferritin) index ≥ 14, but not classified as AI or IDA only  
sTfR-log/ferritin index is calculated as sTfR (nmol/L)/log10(ferrritin (ng/ml)) 
 
*Values for TB cases at diagnosis were significantly different compared with non-TB cases (TST-positive and TST-negative contacts 
combined) (Mann-Whitney test; P <0.05)   
#Conditions were significantly more frequent in TB cases (at diagnosis) vs. non-TB cases (TST-positive and TST-negative contacts 
combined)(Fisher’s exact test; P <0.05)  
Values of nutritional status indicators, hematological indicators and iron indicators for TB cases after six months of treatment were 
not statistically different from those observed in TST-negative contacts (Mann-Whitney test; P <0.05)  
 
 
   105 
 
 
 
 
 
Table 5.2. Predictors of anemia etiologies using multiply imputed values for anemia, IDA, AI, 
and IDA+AI amongst TB cases throughout TB treatment 
 Anemia IDA  AI  IDA+AI 
Duration of treatment  
TB diagnosis Reference 
2-Months 
 
0.84 
(0.33 to 2.1) 
1.27 
(0.36 to 4.52) 
0.84 
(0.33 to 2.18) 
2.07 
(0.76 to 5.67) 
 
6-Months 
 
0.35 
(0.14 to 0.86) 
 
0.82 
(0.23 to 2.93) 
 
0.19 
(0.06 to 0.67) 
 
0.85 
(0.28 to 2.61) 
 
Mixed-effects logistic regression was utilized to model the binary outcomes of anemia, IDA, AI, 
and IDA+AI.  Models were adjusted for age, gender and TB treatment duration.   
Forty-five TB cases having samples from three time points were used in this analysis providing a 
total of 135 possible data points.  Due to missing data and model convergence, the total 
number of data points utilized in this model ranged from 125 to 133.   
Anemia= male Hb <13 g/dL, female Hb <12 g/dL (28) 
Iron deficiency= MCV <80 fL (29) 
AI= individuals who are anemic plus have an sTfR/log(ferritin) index < 14 (30) 
IDA= individuals who are anemic plus iron deficient, but were not classified as AI 
IDA+AI= individuals who are IDA plus have an sTfR/log(ferritin) index ≥ 14, but not classified as 
AI or IDA only  
sTfR-log/ferritin index is calculated as sTfR (nmol/L)/log10(ferrritin (ng/ml)) 
 
 
 
 
 
 
   
    
  106 
 
Figure 5.1. Risk factors for all-cause anemia and cause-specific anemia in 125 participants with 
active TB cases at TB diagnosis, Mycobacterium tuberculosis Complex infected (TST-positive) 
and uninfected (TST-negative) contacts at study recruitment 
BMI=Body Mass Index; sTfR= soluble transferrin receptor; AI= Anemia of Inflammation; IDA= 
iron deficiency anemia 
Univariate logistic regression was utilized to model the relationship between anemia (all forms) 
(n=51/125), IDA (n=19/125), AI (n=28/125) and IDA+AI (n=11/125) with age, sex, BMI (≥18.5 vs 
<18.5) and TB (TB vs no active TB).  In the “TB adjusted” regression model, the TB variable was 
adjusted for age, gender and BMI. 
Anemia= male Hb <13 g/dL, female Hb <12 g/dL (28) 
Iron deficiency= MCV <80 fL (29) 
AI= individuals who are anemic plus have an sTfR/log(ferritin) index < 14 (30) 
IDA= individuals who are anemic plus iron deficient, but were not classified as AI 
IDA+AI= individuals who are IDA plus have an sTfR/log(ferritin) index ≥ 14, but not classified as 
AI or IDA only  
sTfR-log/ferritin index is calculated as sTfR (nmol/L)/log10(ferrritin (ng/ml) 
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Figure 5.2.  Iron status biomarkers in active TB cases at TB diagnosis, Mycobacterium 
tuberculosis Complex infected (TST-positive) and uninfected (TST-negative) contacts.  Mann-
Whitney test. 
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Figure 5.3. Longitudinal changes in ferritin, hepcidin, soluble transferrin receptor (sTfR), 
transferrin and hemoglobin concentrations among TB cases during treatment. Wilcoxon 
matched-pairs signed rank test.  
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Discussion 
All-cause anemia was a common comorbidity in TB, with the majority of individuals 
classified as AI. While AI was largely resolved after completion of TB therapy without iron-
specific interventions, this approach alone was insufficient to resolve all forms of anemia. 
Anemia that had a sole or combination iron-responsive component (e.g. IDA, or IDA+AI, 
respectively) made up almost half of all-cause anemia at TB diagnosis and remained mostly 
unresolved by the end of TB treatment.  Resolution of iron-responsive anemia calls for iron-
focused interventions, and in the context of TB and malnutrition, this study demonstrates for 
the first time that the window of opportunity to intervene with iron appears to open as early as 
two months after TB treatment initiation.  
Others have also reported that anemia is a common comorbidity at TB diagnosis (11-16) 
and that it is partially resolved with TB treatment (14, 15), but the evidence presented here 
goes further suggesting AI is the predominant anemia classification at TB diagnosis. These data, 
while novel, are consistent with what is known about the biology of anemia.  AI is a 
consequence of inflammation and is most often the result of inflammation-related pathologies 
such as short erythrocyte life-span, poor erythrocyte iron incorporation and decreased 
sensitivity to or supply of erythropoietin (17). IDA and IDA+AI, on the other hand, occur as a 
result of negative iron balance alone or in combination with inflammation, respectively. 
Treating TB enables recovery from AI via reduced inflammation and also likely leads to 
improved dietary intake.  While the latter may independently contribute to normalizing iron 
status through improved iron balance, evidence suggests that this contribution is insufficient to 
resolve iron-responsive anemia.  
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Treating iron-responsive anemia in the presence of inflammation and infection is 
complicated.  From a safety perspective, changes in iron metabolism under inflammatory 
conditions may create a favorable environment for pathogen iron acquisition and growth. The 
combination of iron supplementation and inflammation-mediated low Tf concentration could 
lead to an increase in non-transferrin bound or ‘free’ iron.  This unbound iron has been 
implicated in previous reports detailing poor health outcomes following iron supplementation 
in settings where infection is common (31). Moreover, inflammation leads to elevated levels of 
the iron regulatory peptide, hepcidin (reviewed in (32)), which controls enterocyte and 
macrophage iron efflux.  Elevated hepcidin has been shown to forecast non-responsiveness to 
oral iron therapy (33), suggesting that irrespective of the amount of iron being delivered, iron 
balance will not be restored when inflammation levels remain high.  The key to resolving iron-
responsive anemia in this context appears to be to first control inflammation, and then consider 
iron interventions at time when hepcidin levels are reduced.  
By monitoring concentrations of hepcidin and other iron biomarkers throughout TB 
treatment, optimal timing for a possible iron intervention may be identified. In this study, high 
concentrations of hepcidin at TB diagnosis indicated that an iron intervention would likely be 
ineffective.  However, the dramatic drop in hepcidin concentrations that we observed after just 
two months of TB treatment suggests that an opportunity to effectively and safely intervene 
with iron and treat iron-responsive anemia opens up prior to the completion of TB treatment.  
Further studies are needed to validate this strategy, determine which markers are the best to 
pinpoint this intervention opportunity, and to identify parameters that constitute safe and 
effective iron supplementation at an individual level.   
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An important, but elusive goal in TB treatment and control is the identification of 
individuals at risk to transition from MTBC-infected and stable latent TB infection (LTBI) to 
active TB disease.  Based on the iron biomarker patterns observed in this study, which 
differentiated between active untreated TB cases and TST-positive contacts, iron biomarkers 
appear to have potential to contribute to the development of risk profiles for the transition 
from LTBI to TB.  However, in order to properly evaluate iron-associated proteins as disease 
transition biomarkers a TB case-contact study with serial biological archives from TB contacts 
that progress to active TB is needed.  Alternatively, an existing cohort set in a TB endemic 
region with serial biological samples and well-characterized TB-related participant 
characteristics may already exist.  Such studies would build on existing evidence indicating that 
higher concentrations of ferritin (21) and hepcidin (22, 34) as well as lower concentrations of Tf 
(21) and hemoglobin (21) are risk factors for incident TB with HIV co-infection.  
Key strengths of this study include the analysis of multiple iron biomarkers to enable 
specific classification of anemia types in TB contacts compared to TB cases, and in TB cases 
throughout treatment.  These data contributes to a better understanding of appropriate 
treatment options and timing in settings where complex anemia from infection and nutrition-
related etiologies coexist.   Limitations include the lack of consensus definitions for anemia 
classification that restrict comparability with studies using different anemia definitions. While 
the sensitivity analyses suggests HIV infection was not a significant factor in this dataset, the 
role of HIV infection, including stage of disease or immunosuppression and HIV treatment, 
needs to be specifically confirmed in future research.   In addition, it will be important to 
confirm the clinical relevance of these findings across different subgroups including hereditary 
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iron disorders that are uncommon in The Gambia (35), and in smokers and pre- and post-
menopausal women with potentially differential iron metabolism and TB outcomes.   
Conclusion 
Anemia comorbidity is common in TB and predominantly due to AI at TB diagnosis.  
While TB treatment was associated with resolution of AI, TB treatment alone did not eliminate 
all AI, and the prevalence of IDA and IDA+AI was essentially unchanged following TB treatment.  
This underscores the importance of utilizing iron biomarkers to classify anemia type and then 
matching anemia interventions to causes.  Changes in iron biomarker concentrations during TB 
treatment may inform timing of iron interventions. Importantly, hepcidin concentrations 
decreased dramatically after two months of treatment, revealing a potential window of 
opportunity for iron-based interventions aimed at resolving iron-responsive anemia.  In light of 
this evidence, strategies to identify and treat anemia in TB should be re-evaluated to include 
classification of anemia and specific timing considerations that can be used to guide effective 
anemia intervention. 
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CHAPTER 6 
Conclusions and Recommendations 
Contribution to the Literature 
In light of evidence supporting roles for iron in HIV, HIV/TB co-infection, TB and anemia, 
this research aimed to characterize iron homeostasis in these contexts in order to provide 
insight into pathogenesis and to explore their potential clinical utility of iron homeostasis 
biomarkers.   This was accomplished via the evaluation of iron homeostasis biomarker 
concentrations at HIV diagnosis, upon contact with a known infectious TB case, and throughout 
TB treatment.  
While the relationship between hemoglobin and HIV is well characterized, few studies 
have expanded their inquiries to include other iron homeostasis biomarkers and even fewer 
have explored those biomarkers in relation to incident TB, mortality, TB susceptibility and TB-
associated anemia.   
This research includes one of just two studies that has examined the relationship 
between the iron homeostasis biomarker, hepcidin, and incident TB in HIV and it also includes 
the first and only study to describe the relationship between hepcidin and mortality in an HIV-
seropositive cohort.  The use of principal components analysis in the latter study added an 
extra dimension and enabled a more comprehensive understanding of the mechanisms 
involved.  The investigation into iron homeostasis biomarkers in contacts of infectious TB cases 
is also novel.  Additionally, this research is one of just a few studies to characterize iron 
homeostasis biomarkers throughout TB treatment and the first and only study to do so in such 
a way that informs the timing of potential anemia interventions.  
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Conclusions 
Chapter 2 
1. The highest quartile of hepcidin concentrations at HIV diagnosis accounted for >40% of 
all incident TB cases. 
2. Comparing the upper hepcidin quartile to the lower three quartiles combined revealed a 
two-fold increase in the incidence of TB [unadjusted incident rate ratio (IRR); 95% 
CI=2.05; 1.01 to 4.16] 
3. Hepcidin’s ability to predict incident TB was equal to or better than covariates 
representing greater immunosuppression, inflammation and lower BMI.  
4. Hepcidin may modulate the host environment to favor Mycobacterium tuberculosis 
and/or be a viable proxy biomarker for subclinical TB.   
 
Chapter 3 
1. Hepcidin at HIV diagnosis was positively correlated with ferritin, inflammation and 
immunosupression and inversely correlated with hemoglobin and transferrin.   
2. There was a dose response relationship between greater hepcidin at HIV diagnosis and 
mortality. 
3. Whether hepcidin is a symptom of advanced disease stage and its associated 
inflammation, or a factor that contributes to that advanced disease stage and mortality 
is not clear.  There is, however, evidence linking elevated hepcidin to HIV propagation, 
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suggesting that the association between hepcidin and mortality may be driven (in part) 
by a biological affect of hepcidin.   
4. Hepcidin is linked with complex iron distribution that is associated with inflammation, 
anemia and mortality in HIV infection.  This is particularly relevant since anemia is 
associated with poor prognoses in HIV and many people suffer from anemia prior to and 
during ART. 
 
Chapter 4 
1. Lower transferrin concentration was associated with a greater likelihood of TB at any 
time point and earlier TB progression was linked to elevated concentrations of hepcidin 
and ferritin in household contacts of infectious TB cases. 
2. There is a plausible biological mechanism in which ‘too much iron’, or likely too much 
iron sequestered in macrophages as ferritin or bound to circulating transferrin, leads to 
increased TB susceptibility via improved efficiency of Mtb iron acquisition. 
3. Targeted monitoring of iron homeostasis biomarker profiles in TB contacts may help to 
identify those at greater risk for progression to TB, which could reduce delays in TB 
diagnosis and/or treatment, improve TB-related health outcomes and decrease TB 
transmission. 
 
Chapter 5 
1. Anemia was a common co-morbidity in TB and a significant portion of it was classified as 
anemia of inflammation (AI).  While TB treatment resolved AI, it was not sufficient to 
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resolve all types of anemia.  Anemia with iron responsive components (e.g. Iron 
deficiency anemia (IDA), or IDA+AI) made up almost half of all-cause anemia at TB 
diagnosis and was mostly unresolved after TB treatment. 
2. Resolving iron responsive anemia requires iron interventions, which are ineffective and 
potentially unsafe when hepcidin concentrations are high, such as at TB diagnosis.  After 
2 months of TB treatment, however, hepcidin concentrations decrease, opening a 
window of opportunity for iron intervention.   
3. Routine classification of anemia type and monitoring of iron homeostasis biomarkers 
during TB treatment may inform timing for safe and effective iron interventions.   
 
Recommendations for Future Work 
Chapter 2 
1. More data are needed from diverse settings to confirm the association between 
elevated hepcidin and incident TB in HIV.  Studies similar to the one described 
conducted in different population settings and with different age groups could clarify 
the roles of environmental, genetic and cultural factors and would provide further 
insight into hepcidin’s proposed biological role in incident TB in HIV. 
2. Data on hepcidin concentrations are needed from HIV-seropositive populations on ART.  
Access to ART is increasing rapidly, resulting in decreased immune activation, 
immunosuppression and viral load in people living with HIV.  Since hepcidin is regulated 
by inflammation it will be important to understand how ART affects its association with 
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incident TB and its proposed biological role as a factor contributing to favorable 
conditions for Mtb.  
3. Further investigations into the mechanisms governing the relationship between iron and 
Mtb are warranted.  If, as proposed, elevated hepcidin favors Mtb growth; in vitro 
studies may be able to demonstrate links between hepcidin-mediated macrophage iron 
sequestration and increased Mtb iron acquisition and/or Mtb propagation.  These 
investigations could provide the biological basis for routine monitoring of hepcidin 
concentrations in people infected with Mtb and/or those living with HIV (many of whom 
are likely to be infected with Mtb).   
 
Chapter 3 
1. As with the recommendations for future research for chapter 2, more data are needed 
from diverse settings and population groups to confirm the association between 
elevated hepcidin and mortality in HIV, as well as the correlations between iron 
homeostasis biomarkers, anemia, immunosuppression and inflammation.  In addition, 
data from HIV-seropositive populations on ART are needed in order to shed light on the 
complex relationship between inflammation, anemia, iron homeostasis and mortality in 
the context of ART.   
2. Further research related to the hierarchy of hepcidin regulation is warranted.  We know 
that hepcidin expression is regulated by iron status, inflammation, erythropoiesis and 
hypoxia, but the hierarchy is not clear and this complicates efforts to untangle the 
effects caused by changes in hepcidin concentration from other factors.  
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3. Experimental data on the effectiveness of hepcidin interventions (e.g., anti-
inflammatories, hepcidin-neutralizing antibodies) is needed.  These interventions seem 
promising from the perspective of decreasing anemia, but they may interfere with iron 
homeostasis and the host-pathogen competition for iron.  
 
Chapter 4 
1. Further studies that are similar to the one described in chapter 4 are needed.   Future 
studies must have larger sample sizes, HIV-free populations, age variation and 
longitudinal collection of biological samples leading up to the diagnosis of TB.  While the 
nature of TB pathogenesis makes it difficult to conduct theses studies, the conclusions 
drawn in chapters 2 and 4 make a case for prioritizing this research.  
2. Similar to the future research recommended for Chapter 2, investigation into a plausible 
biological mechanism in which a specific iron homeostasis profile favors Mtb iron 
acquisition is warranted.   In vitro studies that examine siderophore iron acquisition 
relative to changes in host iron homeostasis may be able to elucidate a mechanism that 
explains the results reported in this chapter.  
3. Working under the assumption that iron homeostasis biomarkers provide clinically 
useful information related to the likelihood of developing of active TB disease, improved 
technology to monitor the biomarkers should be a priority.  Currently, access to 
laboratories capable of monitoring hepcidin, ferritin, transferrin and sTfR in low 
resource settings is extremely limited.  Initiatives to develop cost-effective point-of-care 
assays for these biomarkers are needed.  
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Chapter 5 
1. Greater efforts to match anemia interventions to causes are needed, particularly in low 
resource settings.   
2. Anemia of inflammation is not limited to TB.  It is likely that the evidence described in 
chapter 5 and its implications for anemia interventions are relevant for other diseases 
that cause inflammation.  Studies investigating anemia types and iron homeostasis 
biomarkers in other disease contexts are warranted.   
3. There is debate surrounding the safety and efficacy of iron supplementation in areas 
where infectious disease is endemic. Recent evidence suggests that hepcidin 
concentrations, which regulate dietary iron absorption as well as macrophage and 
enterocyte iron efflux, are the key to determining when oral iron supplementation will 
be safe and effective.  Experimental studies that validate hepcidin’s key role in this 
determination and identify parameters that constitute safe and effective iron 
supplementation are needed.   
4. Studies that evaluate iron homeostasis biomarkers throughout TB treatment with 
increased frequency are crucial to the accurate identification of anemia intervention 
opportunities.  Pinpointing these opportunities should lead to more targeted, more 
effective anemia interventions.   
 
 
 
 
 
   
    
  123 
APPENDIX 1: ROLES OF IRON HOMEOSTASIS BIOMARKERS  
 Established iron-related function Biological mechanisms of 
effect 
transferrin (Tf) The Tf protein transports absorbed ferric 
iron from intestinal enterocytes to cell-
associated TfR.   This allows iron transfer 
from the extracellular to intracellular 
environments. 
Known source of Mtb.-
acquired host iron.  
Hemoglobin 
(Hb) 
Hb contains the primary concentration 
of heme iron, typically accounting for 
about 65% of total body iron.  
Known source of M.tb.-
acquired host iron via Mtb. 
heme acquisition system.  
Hepcidin Acts as a negative regulator of iron 
export  - stimulated via inflammation 
and/or sufficient iron status.  
Promotes macrophage iron 
retention.  Negative regulator 
of dietary iron absorption.  
 ferritin Plasma ferritin concentrations are 
directly correlated with macrophage 
ferritin acting as an iron storage depot. 
A known source of Mtb.-
acquired iron.  Ferritin 
concentrations are sensitive to 
inflammation and labile iron 
pool. 
 soluble 
transferrin 
receptor (sTfR) 
Soluble transferrin receptor 
concentrations are directly associated 
with cellular TfR concentrations - TfR 
allows Tf-bound iron to enter cells.  
sTfR concentrations are 
correlated with the amount of 
iron in the cellular labile iron 
pool (via IRP/IRE activity).  
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2: ABSTRACT ACCEPTED FOR POSTER PRESENTATION AT KEYSTONE SYMPOSIA: HOST RESPONSE 
IN TUBERCULOSIS. WHISTLER, BRITISH COLUMBIA 2013.   
Accumulation of transferrin receptor 1 (TFRC) mRNA in human caseous tuberculosis 
granuloma may affect Mycobacterium tuberculosis-induced lipid dysregulation 
 
Minchella PA, Russell DG, McDermid JM  
 
The caseous human tuberculosis (TB) granuloma is induced by a local adaptive immune 
response to Mycobacterium tuberculosis (Mtb) infection and subsequent necrosis of infected 
macrophages.  It is a hallmark of active human TB disease.  Studies suggest that host iron 
homeostasis may affect Mtb survival.  Similarly, studies have noted that dysregulation of lipid 
metabolism may contribute to Mtb persistence.  We investigated differences in genome-wide 
expression observed in tissue from caseous TB granulomas (3 subjects) and normal lung 
parenchyma using a publically accessible dataset.  Using the Ensembl genome browser, we 
identified 100 genes involved in human iron homeostasis.  Of the 100 genes identified, 48 
showed significantly different levels of expression (p<0.05) and 47/48 genes showed increased 
expression in the caseous TB granuloma.  The greatest change in expression, representing a 
565-fold increase, was observed for transferrin receptor 1 (TFRC).  Based on the known 
regulatory mechanisms of transferrin receptor 1, this suggests that cells within the granuloma 
may be characterized by decreased intracellular iron – potentially affecting Mtb-induced lipid 
dysregulation.  Lipid dysregulation and associated foamy macrophage formation are mediated 
through cholesterol efflux transporters ABCA1 and ABCG1, both of which have been shown to 
be sensitive to intracellular iron levels.  Alternatively, the increase in granuloma TFRC 
expression could be indicative of increased host iron efflux into the granuloma.  As expected, 
ferritin (FTL and FTH1) and SLC11A1 were up regulated, both of which have been linked to TB 
susceptibility.  How the host and pathogen utilize essential nutrients during TB pathogenesis is 
important for further understanding of the transition from latency to disease. 
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APPENDIX 3: ABSTRACT ACCEPTED FOR POSTER PRESENTATION AT THE 7TH INTERNATIONAL 
AIDS SOCIETY (IAS) CONFERENCE ON HIV PATHOGENESIS, TREATMENT AND PREVENTION.  
KUALA LUMPUR, MALAYSIA 2013.   
Elevated hepcidin concentrations at HIV diagnosis are associated with increased mortality 
  
Peter A. MINCHELLA, Andrew E. ARMITAGE, Bakary DARBOE, Momodou W. JALLOW, Gilleh 
THOMAS, Assan JAYE, Joann M. McDERMID, Andrew M. PRENTICE 
 
BACKGROUND: Studies across diverse populations have demonstrated that iron redistribution 
and anemia are associated with increased morbidity and mortality during HIV infection.  
Systemic inflammation upregulates hepcidin—blocking iron absorption, release from 
macrophages and availability to erythroid cells. 
 
METHODS: Plasma hepcidin concentrations at HIV diagnosis were retrospectively measured in a 
subset of HIV Clinical Cohort participants based at the Medical Research Council Unit, The 
Gambia.  Archived data and plasma samples were obtained from 196 HIV-1 and HIV-2 
antiretroviral naïve participants.  Hepcidin concentrations were measured using a competitive 
EIA (Bachem).  Cox regression was used to investigate the relationship with mortality. 
 
RESULTS: At HIV diagnosis, median age was 34 years, 55% were female, 61% were HIV-1, 
median absolute CD4 count was 250 cells/mm3 and participants were followed a median of 644 
days.  Median hepcidin concentration (interquartile) was 22.1 (3.3; 85.9) ng/ml among all 
participants.  Hepcidin was positively correlated with plasma ferritin and transferrin saturation 
but inversely correlated with hemoglobin, transferrin and soluble transferrin receptor 
concentrations.  In univariate analysis, elevated hepcidin was significantly associated with 
increased probability of all-cause mortality in a dose-dependent manner (upper tertile vs. 
lowest tertile incidence rate ratio, IRR 3.45; 95% CI = 2.19 to 5.42 and middle vs. lowest 2.14; 
1.35 to 3.40).  This association was only slightly attenuated by the inflammation biomarker, α-1-
antichymotrypsin, and remained statistically significant.  Inclusion of factors considered a priori 
to be predictors of mortality attenuated the observed association (model adjusted for absolute 
CD4, gender, body mass index, age at diagnosis 1.56; 0.87 to 2.80 – upper vs. lowest tertile and 
1.42; 0.87 to 2.32 – middle vs. lowest tertile).  
 
CONCLUSIONS:  Elevated hepcidin concentrations were associated with increased mortality in 
this HIV seroprevalent cohort.  Hepcidin, like other biomarkers of iron homeostasis, is 
associated with a complex iron redistribution phenomenon that occurs in people who are at 
greater risk of mortality in HIV infection. Hepcidin-mediated blockage of iron supply for 
erythropoiesis may contribute to the pathogenesis of HIV-associated anemia that is associated 
with increased morbidity and mortality.  Hepcidin antagonists may be a potential target for 
treatment of HIV-associated iron redistribution and anemia. 
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APPENDIX 4: ABSTRACT ACCEPTED FOR ORAL PRESENTATION AT EXPERIMENTAL BIOLOGY 2014. 
SAN DIEGO, CA 2014.  
Elevated concentrations of iron biomarkers are resolved by standard tuberculosis (TB) 
treatment 
Minchella PA, Donkor S, Sutherland JS, McDermid JM 
Studies suggest that iron status affects the risk of developing TB as well as TB treatment 
outcomes, but evidence characterizing iron status during TB treatment is limited. The objective 
of this research was to examine biomarkers of host iron status prior to and during TB treatment.  
Baseline levels of ferritin, hepcidin, soluble transferrin receptor (sTfR) were measured in 45 TB 
patients as well as 42 tuberculin skin test (TST)+ and 44 TST- controls in The Gambia.  In TB 
patients, measurements of serum and plasma iron biomarkers were repeated at 2 months after 
initiation of standard TB treatment and again at the completion of treatment (6 months).  Prior 
to the start of treatment, median concentrations of ferritin (164.5 ng/ml; IQR 95.65 to 251.8), 
hepcidin (83.98 ng/ml; IQR 43.84 to 144.9), and sTfR (29.36 nM; IQR 23.74 to 36.81) were 
significantly different in TB patients compared with TST+ and TST- controls. In TB patients, 
ferritin, hepcidin and sTfR decreased significantly during the first two months of treatment and 
maintained significantly lower concentrations through treatment completion. Elevated levels of 
iron biomarkers in TB patients appear to normalize following 2 months of TB treatment.  
Understanding fluctuations in iron status during TB treatment may assist with the clinical 
management of TB, particularly in regions with high burdens of iron malnutrition and 
corresponding iron supplementation programs. 
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APPENDIX 5: STANDARD OPERATING PROCEDURE (SOP) FOR ANALYSIS OF HEPCIDIN 
CONCENTRATION IN HIV+ PLASMA SAMPLES  
This SOP was developed in collaboration with Dr. Andrew Armitage and Bakary Darboe for the 
Bachem Hepcidin-25 Enzyme immunoassay.  Since this assay underwent extensive optimization, 
this SOP is quite detailed and includes recommendations for kit pooling.  
1. Background  
The Bachem Hepcidin-25 EIA is a competitive enzyme immunoassay for the quantitative 
in vitro diagnostic measurement of Hepcidin in plasma and serum.  Hepcidin is a 25-
amino acid, cysteine-rich peptide hormone, produced by the hepatocyte and has 
important role for iron homeostasis. Hepcidin controls plasma iron levels by regulating 
the absorption of iron from the intestine and the release of iron in the macrophage and 
hepatocyte. It is secreted in response to iron overload and inflammation. The 
production decreases in iron depletion. Increased hepcidin concentrations lead to 
decreased iron absorption and decreased hepcidin concentrations will cause increased 
iron release from the enterocyte and macrophages. 
2. SAFETY PRECAUTIONS 
 All reagents of this test kit, which contain human serum or plasma, have been tested 
and confirmed negative for HIV I/II, HBsAg and HCV by FDA approved procedures. All 
reagents, however, should be treated as potential biohazards in use and for disposal. 
 Avoid contact with Stop Solution containing 2N HCl. It may cause skin irritation and 
burns. 
 TMB substrate has an irritant effect on skin and mucosa. In case of possible contact, 
wash eyes with an abundant volume of water and skin with soap and abundant water. 
Wash contaminated objects before reusing them. If inhaled, take the person to open air. 
 All blood samples should be treated as potentially infectious and all work done inside a 
certified Cat 3 Biological safety lab. 
 Appropriate safety precautions should be utilized for biohazard material and the 
formaldehyde solution use. 
 Personal protection equipments (PPE) including proper usage of Lab coats, gloves, face 
shield, and biological safety cabinet should be used. 
 All used test tubes, plastic wares and pipette tips are also discarded in disinfectant 
containing VirkonTm 
3. Equipment and Reagents 
Materials required but not provided 
 A microtiter plate calibrated reader (450 ± 10 nm)  
 96-well plate shaker and washer (optional) 
 Test tubes, pipettes and various other standard laboratory items 
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 Calibrated variable precision micropipettes and multichannel pipettes. 
 Absorbent paper. 
 Distilled or deionized water 
 Timer 
 graph paper or software for data reduction 
 
Reagents provided  
 EIA buffer concentrate (50ml 20X concentrate) 
 96-well immunoplate with acetate plate sealer 
 Antiserum (lyophilized powder) 
 Standard (1 ug lyophilized powder) 
 Biotinylated tracer (lyophilized powder) 
 Streptavidin-HRP (100ul 200X concentrate) 
 TMB substrate solution (11ml TBM and H2O2) 
 Stop solution 2N HCl (15ml) 
 Standard diluents 8ml (peptide – free human serum 
Storage 
 When multiple plates are required for the study, aliquoted stocks of reagents should be 
prepared in advanced and stored at -80ºC until use. 
 EIA plates, 20x EIA buffer, Strep-HRP, TMB, and 2N HCl (all supplied) should be stored at 
2-8ºC. 
 All reagents should be brought to room temperature before use. 
 
4. Reagent Preparation:  
Preparation of Stock reagents  
 We suggest that a significant portion of time is allocated for preparation of reagent stocks, 
and that this should probably not be the same day that the first plate is run. 
 Before starting, it is recommended that the volumes suggested below are tested for your 
lab’s particular multichannel pipette arrangements (multichannels, reservoirs etc) – e.g. for 
standards, can 3 x 50µl standard be accurately pipetted from 180µl – is this excess 
sufficient? 
 
Preparation of diluent and standards  
 Bring components to room temperature before commencing. 
 Pool standard diluent from X kits (8ml provided per kit) – mix well. [adjust quantities 
according to the number of samples / kits needed in the project / part of the project.] 
 Reconstitute lyophilised standard (hepcidin peptide) from 1 kit in 1ml pooled diluent = 
1µg/ml (some lyophilised material is likely to stick to the inside of the rubber cap; suggest 
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gently lifting up rubber cap, but not removing it completely - and adding 1ml diluent 
through the available gap). 
 Invert and vortex to ensure hepcidin standard is completely dissolved. 
 Spin down drops of liquid from lid by placing glass vial in 50ml falcon – to ~1500rpm. 
 Carefully remove vial from falcon tube with tweezers. 
 
 Dilute stock hepcidin standard to 25ng/ml – e.g. for 11 kits add 140µl to 5.46ml standard 
diluent in a 15ml falcon tube = total 5.6ml.  (Note this gives an excess).  Adjust volumes as 
necessary according to the number of assays required. 
 2-fold x 10 serial dilution – e.g. for example above, 2.8ml + 2.8ml diluent to generate 5.6ml 
each (for 11 kits with excess, adjust as necessary) of 25ng/ml (S1), 12.5 (S2), 6.25 (S3), 3.125 
(S4), 1.5625 (S5), 0.78125 (S6), 0.391 (S7), 0.195 (S8), 0.098 (S9), 0.049 (S10). 
 Pipette up and down and vortex between each dilution to mix. 
 Aliquot each standard – labelled S1 – S10: 180µl per aliquot is recommended (3 x 50µl = 
150µl needed for triplicate wells in assay); note that this is a 20% excess 
 Also aliquot 360µl standard diluents to tubes labelled S0/Blk to add to (a) No antibody 
control well (Blk) and (b) no hepcidin peptide control (S0) wells on plate (i.e. 6 wells require 
this, not 3). [See suggested plate setup] 
 Place sets of standards S1-S10 + S0/Blk in small bags -80ºC freezer – 1 bag of standards per 
plate. 
 Thaw one bag of aliquots for each plate within an hour of adding to the plate. 
 It is possible to make more sets of aliquots are made than the number of kits (owing to the 
excess built in) – this may be worthwhile to allow for error etc (there is an excess of reagent 
provided – this point is true for biotinylated-hepcidin tracer and antiserum as well).  
Alternatively, we may be able to ‘create’ extra kits in this way (all that would be required 
would be extra coated ELISA plates, TMB, Strep-HRP and 2N HCl).  
 
Preparation of serum diluent aliquots 
 Remainder of standard diluent (peptide free human serum): aliquoted into 1ml and 500µl 
aliquots. 
 Store at -80ºC 
 Appropriate amounts to be thawed for preparation of samples (depending on dilutions 
required) before each plate is run – see general points below. 
 
Preparation of Bt-tracer and antiserum  
 Bring all components to room temperature before commencing. 
 Dilute EIA buffer concentrate 20x: e.g. for 11 kits,10ml EIA buffer concentrate + 190ml 
sterile milliQ water (e.g. in sterile T75 tissue culture flask – normally use another bottle for 
routine washes; this EIA buffer is for reconstitution of Bt-tracer and antiserum). [This only 
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requires EIA buffer concentrate from one kit, adjust volumes if larger numbers of samples 
are required.] 
 Reconstitute Bt-tracer (biotinylated hepcidin) and antiserum samples (rabbit anti-hepcidin 
antiserum) from e.g. 11 kits in 5ml EIA buffer each – total 55ml. 
 Gently lift rubber cap and add 5ml buffer using 5ml pipette through gap without fully 
removing lid (some lyophilised peptide inevitably remains on the cap, so care required). 
 Invert vial and vortex; spin in 50ml falcon tube to remove drops from rubber cap and 
remove from falcon tube using tweezers. 
 Pool antiserum and Bt-tracer samples in e.g. 50ml falcon, or appropriate sized 
polypropylene vessels (polypropylene to minimise risk of peptide/protein sticking to vessel 
walls).  Mix well.  Extreme care is required at this step as these components are not 
provided in significant excess – an error at this point can cost an entire set of kits – very 
expensive! 
 Make 3 x 1.1ml aliquots of both Bt-tracer and antiserum for each plate that is required. 
 Freeze Bt-tracer and antiserum at -80ºC.  
 Additionally – prepare 1ml aliquots of EIA buffer prepared – to be used in the no antibody 
blank control wells in place of hepcidin antiserum.  Store with antiserum in -80ºC freezer. 
 Thaw 3 aliquots per plate within an hour of use = 3.3ml (2.325ml antiserum required per 
plate; 75µl EIA buffer required per plate; 2.4ml Bt-tracer required for 96-well plate). 
 
General points:  
 Bring reagents to room temperature before commencing procedure (typically thaw within 
an hour of use). 
 We have typically found that a starting 1 in 5 (e.g. 40µl + 160µl pooled diluent to give 
sufficient excess: 3 x 50µl diluted sample needs to be added to the plate) or 1 in 6 dilution 
of sample is most likely to give a reading in the linear region of the curve.  Extremes may be 
predicted by serum ferritin data if available, as there is typically a reasonable positive 
correlation between ferritin and hepcidin (i.e. it might be worth diluting to a greater extent 
a sample known to have a very high ferritin, and vice versa for low ferritin). 
 Standards / Samples can be added to / diluted in flat-bottom 96-well plates in columns 1, 4, 
7 and 10 in appropriate positions (see setup below) – for transfer to the EIA plate using 
multichannel pipettes (50µl added). 
 Use plate shakers during incubations – 60rpm as recommended. 
 Ensure no precipitates are present in TMB. 
 We tend to develop the colour in the dark (e.g. under a box). 
 We have found that 10 or 15 minutes is sufficient for development of blue after adding TMB 
(point 12 recommends 30 mins to 1 hr) – in our experience it will overdevelop with longer 
than this.  We typically stop the reaction using 2N HCl at 10 min, to develop the yellow 
colour which is read at 450nm within 10 minutes (it’s normally ok for a little longer than this, 
but aim to read within 10 minutes). 
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 IMPORTANT: bubbles in wells have a significant effect on the readings generated and will 
lead to significant inaccuracy.  Ensure bubbles / foaming is not generated; if bubbles are 
present, use e.g. 10µl pipette tips to try to pop them. 
 Analyse using 4-parameter logistic curve fitting software (often available on software 
associated with ELISA plate reader). 
 
5. Procedure 
Protocol (essentially the same as Protocol V in the Bachem kit handbook) 
 Bring all kit components to room temperature before commencing. 
 Thaw 3 vials of 1.1ml anti-hepcidin antiserum - 25ul per well of antiserum except blank 
wells A1-A3 (add EIA buffer) – multichannel pipette.   
 Incubate at room temperature for 1 hr on shaker. 
 Thaw plasma samples for testing. 
 Dilute plasma samples appropriately in diluent (from aliquots of pooled peptide-free human 
serum).  Suggest 1 in 5 dilution as first test (e.g. 40µl + 160µl diluent – 150µl required for 
triplicate – 3 x 50µl) – see general point about use of flat-bottomed 96-well plate to make 
this more straightforward. 
 Add 50ul standards S1 – S10 in appropriate wells (S9 may be omitted to allow more samples 
to be run) / 50ul diluted plasma samples / 50ul diluent to blank wells (A1-A3 / D4-D6). 
 Incubate 2hr at room temperature on shaker. 
 Thaw 3 x 1.1ml aliquots of Bt-tracer – add 25ul per well. 
 Incubate overnight – 18hr – on shaker in cold room. 
 Day 2: Equilibrate plate to room temperature e.g. 1 hour 
 Briefly spin Streptavidin-HRP vial top get drops off lid – add 60ul to 12ml EIA buffer in e.g. 
15ml falcon tube.- mix well. 
 Taking care not to cross-contaminate during first wash – discard well contents – wash 5 x 
with 300µl EIA buffer (e.g. 2 x 150µl depending on multichannel available) – approx 30ml 
per wash cycle. 
 Add 100ul/well Streptavidin-HRP. 
 Incubate 1 hr at room temperature on shaker 
 Wash 5 x with EIA buffer as above. 
 Add 100µl/well TMB solution to all wells including blanks. 
 Incubate 10-15 mins at room temperature in dark. 
 Stop reactions with 100µl/well 2N HCl 
 Read OD450 within 10 minutes – ensure there are no bubbles present before reading. 
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APPENDIX 6: STANDARD OPERATING PROCEDURE (SOP) FOR ANALYSIS OF FERRITIN 
CONCENTRATION 
This SOP was created for the Enzyme immunoassay for in-vitro-diagnostic quantitative 
determination of ferritin in human serum kit, produced by IBL International.  
Prior to start:  
1. Remove samples/calibrators/controls/solutions (including HRP, wash TMB etc) from 
freezer/fridge at least 1-hour prior to use.  
2. Prepare working solutions of the anti-ferritin-HRP conjugate and wash buffer. 
Preparation of HRP: Dilute 1:50 in assay buffer (ready to use) before use (dilute 500 μl 
HRP in 24.5 mL of assay buffer) 
Preparation of wash buffer: Dilute 1:10 in distilled or deionized water before use (50 mL 
of the wash buffer concentrate in 450 mL of water. 
3. Remove the required number of microwell strips. Reseal the bag and return any unused 
strips to the refrigerator. 
 
Procedure:  
4. Pipette 20 μL of each calibrator (A-F), control (1,2), QA and specimen sample into 
correspondingly labeled wells in duplicate.  
5. Pipette 200 μL of the conjugate working solution (HRP) into each well (use a multichannel 
pipette and a reservoir).  
6. Seal plate, incubate on a plate shaker (200 rpm) for 30 minutes at room temperature. 
7. Wash the wells 5 times with 300 μL of diluted wash buffer (use multichannel pipette) per 
well and tap the plate firmly against absorbent paper to ensure that it is dry.   
8. Pipette 150 μL of TMB substrate into each well at timed intervals.  
9. Incubate on a plate shaker in the dark (cover with aluminum foil) for 13 minutes at room 
temperature (or until calibrator F attains dark blue color for desired OD). = 
10. Pipette 50 μ L of stopping solution (pipette slowly, watch for bubbles) into each well at the 
same timed intervals as in step 7. 
11. Read the plate on a microwell plate reader at 450 nm within 20 minutes after addition of 
the stopping solution. 
12. Plot 4PL curve and impute concentrations 
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APPENDIX 7: STANDARD OPERATING PROCEDURE (SOP) FOR ANALYSIS OF TRANSFERRIN (Tf) 
CONCENTRATION 
This SOP was created for the Transferrin ELISA, produced by Cygnus Technologies.  
Prior to start: 
1. Bring everything to RT 
2. Dilute wash concentrate to 1 liter and store at 4o C (25 ml wash concentrate + 475 
distilled water) 
3. Dilute samples using 3 consecutive 1:100 dilutions (for a final 1:1,000,000 dilution) 
a. Dilution 1: 5 μl sample + 495 μl diluent 
b. Dilution 2: 5 μl dilution 1 + 495 μl diluent  
c. Dilution 3: 5 μl dilution 2 + 495 diluent  
Procedure:  
1. Pipette 50 μl standard, QA, sample into wells 
2. Pipette 100 μl HRP into each well 
3. Cover and incubate while shaking at 400 rpm for 2 hours (vigorously bang out liquid 
over absorbent paper, do not allow wash solution to remain in wells for longer than a 
few seconds, do not allow wells to dry before addition of TMB.   
4. Wash (x4) with (300-350 μl) wash concentrate  
5. Pipette 100 μl TMB into each well  
6. Cover and incubate for 30 minutes (do not shake) 
7. Pipette 100 μl stop solution 
Read at 450/650 nm blanking on zero standard (450 for test wavelength 650 for reference 
wavelength) 
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APPENDIX 8: STANDARD OPERATING PROCEDURE (SOP) FOR ANALYSIS OF SOLUBLE 
TRANSFERRIN RECEPTOR (sTfR) CONCENTRATION 
This SOP was created for the Quantikine IVD human sTfR immunoassay, produced by R&D 
Systems.  
Prior to Start:  
1. Bring all reagents to room temperature before use.  
2. Wash Buffer Concentrate - If crystals have formed in the concentrate, warm to room 
temperature and mix gently until the crystals have completely dissolved. Dilute 20 mL of Wash 
Buffer Concentrate into deionized or distilled water to prepare 500 mL of Wash Buffer.   
3. sTfR Controls - Reconstitute each vial with 200 μL of deionized or distilled water. Vortex.  
Allow Controls to sit for a minimum of 30 minutes before use. Vortex again immediately 
before use.  
All other reagents are ready for use. 
 
Procedure:  
1. Prepare all reagents as directed in the previous sections. 
2. Remove excess microplate strips from the plate frame, return them to the foil pouch 
containing the desiccant pack, and reseal. 
3. Add 100 μL of sTfR Assay Diluent to each well. 
4. Add 20 μL of standard, sample, QA or control per well. Ensure sample addition is 
uninterrupted and completed within 15 minutes. Gently tap the plate frame to mix the well 
contents. Cover with the adhesive strip provided. Incubate for 1 hour at room temperature (18 
- 25° C).  
5. Aspirate each well and wash, repeating the process three times for a total of four washes. 
Wash by filling each well with Wash Buffer (400 μL) using a squirt bottle, manifold dispenser or 
autowasher. Complete removal of liquid at each step is essential to good performance. After 
the last wash, remove any remaining Wash Buffer by aspirating or by decanting. Invert the plate 
and blot it against clean paper towels.  
6. Add 100 μL of sTfR Conjugate to each well. Cover with a new adhesive strip. Incubate for 1 
hour at room temperature. 
7. Repeat the aspiration/wash as in step 5. 
8. Add 100 μL of Substrate to each well. Incubate for 30 minutes at room temperature in the 
dark.  
9. Add 100 μL of Stop Solution to each well. If color change does not appear uniform, gently tap 
the plate to ensure thorough mixing. 
10. Determine the optical density of each well within 30 minutes, using a microplate reader set 
to 450 nm. If wavelength correction is available, set to 540 nm or 570 nm. If wavelength 
correction is not available, subtract readings at 540 nm or 570 nm from the readings at 450 nm. 
This subtraction will correct for optical imperfections in the plate. Readings made directly at 
450 nm without correction may be higher and less accurate.  
 
“0 standard” is the plate blank; Plot with a 4PL curve* 
